

Identification of bivalent ligands with melatonin receptor agonist and fatty acid amide hydrolase (FAAH) inhibitory activity that exhibit ocular hypotensive effect in the rabbit

Gilberto Spadoni, Annalida Bedini, Lucia Furiassi, Michele Mari, Marco Mor, Laura Scalvini, Alessio Lodola, Andrea Ghidini, Valeria Lucini, Silvana Dugnani, Francesco Scaglione, Daniele Piomelli, Kwang-Mook Jung, Claudiu T Supuran, Laura Lucarini, Mariaconcetta Durante, Silvia Sgambellone, Emanuela Masini, and Silvia Rivara

J. Med. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.jmedchem.8b00893 • Publication Date (Web): 20 Aug 2018

Downloaded from <http://pubs.acs.org> on August 24, 2018

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts

1
2
3 **Identification of bivalent ligands with melatonin receptor agonist and fatty acid amide**
4 **hydrolase (FAAH) inhibitory activity that exhibit ocular hypotensive effect in the rabbit**
5
6
7
8

9 Gilberto Spadoni,^a Annalida Bedini,^a Lucia Furiassi,^a Michele Mari,^a Marco Mor,^b Laura Scalvini,^b
10 Alessio Lodola,^b Andrea Ghidini,^b Valeria Lucini,^c Silvana Dugnani,^c Francesco Scaglione,^c
11 Daniele Piomelli,^{d,b} Kwang-Mook Jung,^d Claudiu T. Supuran,^e Laura Lucarini,^f Mariaconcetta
12 Durante,^f Silvia Sgambellone,^f Emanuela Masini,^f Silvia Rivara^{b*}
13
14
15
16
17
18
19
20
21

22 ^a Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino “Carlo Bo”, Piazza
23 Rinascimento 6, I-61029 Urbino, Italy.
24
25

26 ^b Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parco
27 Area delle Scienze 27/A I-43124 Parma, Italy.
28
29

30 ^c Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano, Via Vanvitelli
31 32, I-20129 Milano, Italy.
32
33

34 ^d Department of Anatomy and Neurobiology, School of Medicine, University of California, Irvine,
35 92697, California, USA.
36
37

38 ^e Dipartimento NEUROFARBA, Sezione di Scienze Farmaceutiche e Nutraceutiche, Università
39 degli Studi di Firenze, via Ugo Shiff 6, I-50019 Sesto Fiorentino (FI), Italy.
40
41

42 ^f Dipartimento NEUROFARBA, Sezione di Farmacologia e Tossicologia, Università degli Studi di
43 Firenze, Viale G. Pieraccini 6, I-50019 Firenze, Italy.
44
45
46
47
48
49

50 * Corresponding author
51
52
53
54
55
56
57
58
59
60

Abstract


Activation of melatonin receptors and inhibition of fatty acid amide hydrolase (FAAH) have both shown potential benefits for the treatment of glaucoma. To exploit the combination of these biological activities in single therapeutic agents, we designed dual-acting compounds sharing the pharmacophore elements required for the two targets, in search for balanced potencies as MT₁/MT₂ agonists and FAAH inhibitors. In particular, the N-anilinoethylamide scaffold, previously developed for melatonergic ligands, was decorated at *meta* position with a polymethylene linker bound to an O-arylcarbamate group, substituted according to known structure-activity relationships for FAAH inhibition. For the most active series, the N-anilinoethylamide portion was also replaced with the indole scaffold of melatonin. O-biphenyl-3-ylcarbamate derivatives were characterized by remarkable and balanced activity at both targets, in the nanomolar range for compound **29**. Topical administration reduced elevated intraocular pressure in rabbits, with a longer action and improved efficacy compared to the reference compounds melatonin and URB597.

Introduction

Glaucoma an optic neuropathy characterized by characterized by high intraocular pressure (IOP) and progressive death of retinal ganglion cells (RGC). Chronically elevated IOP itself is a risk factor for the development of glaucoma and can lead to visual field impairment and loss of visual function as a consequence of optic nerve damage.¹ Current first-line treatment of this condition is generally based on daily topical administration of therapeutics aimed at lowering IOP. These drugs counteract the leading causes of high IOP, i.e., they reduce the production of aqueous humor or promote its impaired outflow through the trabecular meshwork or the uveoscleral pathway. Widely used compounds are β -adrenergic antagonists, α_2 -agonists, carbonic anhydrase inhibitors, prostaglandin analogs and miotic parasympathetic agents.² Combinations of drugs are also available for those patients in which IOP is not properly controlled by a single agent. They can be treated either with concomitant dosing of multiple drugs or with fixed-combination formulations. Concomitant dosing, while being safe and effective, often suffers from limited patient compliance due to several reasons, such as inconvenience, confusion caused by multiple bottles, time required to administer drops and frequency of use.³ Nonadherence to medical prescription reduces treatment effectiveness and leads to disease progression and visual field loss. Fixed-combination formulations simplify the treatment regimen and offer advantages not only in terms of improvement in patient satisfaction and adherence to treatment, but also reduce exposure to ophthalmic preservatives improving tolerability, avoid washout effects and may reduce cost of treatment.⁴ On the other hand, fixed combinations have some disadvantages related to the diminished flexibility of individualized patient care, being not possible to titrate the dose or split the timing of doses.^{5,6} Moreover, combination of drugs into one medication could in principle lead to drug interactions, instability of combined molecules and the emergence of unique adverse events.⁷ In light of these limitations, a hybrid ligand able to interact with multiple targets involved in the regulation of IOP might offer several advantages, related to patient compliance given the reduced number of administrations and time required and to formulation simplification, stability and shelf-life of the product.

1
2
3 Physicochemical properties of hybrid ligands might also differ from those of single acting agents,
4 which could favor the onset and maintenance of pharmacological activity. Therefore, despite the
5 availability of several active principles and their combinations, the search for new IOP lowering
6 agents is highly active and aims at developing more potent compounds with a more persistent action
7 and lower side effects compared to currently available drugs.
8

9
10
11 The neurohormone melatonin (MLT, **1**, Figure 1) has significant IOP-lowering properties.^{8,9} MLT
12 is primarily produced by the pineal gland with highest concentrations reached at night. A number of
13 biological activities have been ascribed to MLT, ranging from central nervous system (CNS)-
14 related activities, such as coordination of circadian rhythms and neuroendocrine processes, to
15 peripheral effects, related, for example, to regulation of the immune system, glucose handling and
16 cardiovascular homeostasis. In mammals, the majority of MLT actions are driven by the activation
17 of the two G-protein-coupled receptors named MT₁ and MT₂ expressed in the CNS and in the
18 periphery, which signal photoperiodic information and regulate physiological functions.^{10,11} Other
19 binding sites have been described for MLT, such as the MT₃ binding site, which has been identified
20 with the cytosolic enzyme quinone reductase 2, nuclear transcription factors of the retinoic acid
21 superfamily, and other proteins such as calmodulin and calreticulin.¹² Moreover, MLT exerts direct
22 antioxidant effects at high concentrations, which can be related to different biological activities
23 observed after its administration. MLT is produced locally in the eye and its receptors have been
24 identified in several areas, such as in the retina, ciliary body, cornea, lens and sclera.¹³ Topical and
25 systemic administration of MLT has been shown to transiently reduce IOP in normotensive and
26 hypertensive/glaucomatous animals, such as mice,¹⁴ rabbits,¹⁵ and monkeys,¹⁶ as well as in
27 humans.^{8,17} MLT potentiates the IOP lowering effect exerted by the adrenergic system, as it
28 increases expression of the α_2 and reduce expression of the β_2 adrenergic receptors that control the
29 synthesis and drainage of aqueous humor in ciliary nonpigmented epithelium.¹⁸ Besides the natural
30 ligand, synthetic MLT receptor agents,⁹ such as agomelatine,¹⁹ IIK7¹⁵ and 5-MCA-NAT,¹⁶ have
31 shown IOP lowering effects.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



13 **Figure 1.** Melatonin and FAAH inhibitor URB597.


14
15
16
17 Reduction of IOP is also a well-known effect observed in cannabis users.²⁰ In fact, a functional
18 endocannabinoid system, which includes endogenous cannabinoids, enzymes involved in their
19 synthesis and deactivation and the cannabinoid receptors CB₁ and CB₂, has been identified in eye
20 tissues and cells, comprising retina and ciliary body.²¹ Reduction of IOP has been observed after
21 administration of endogenous or exogenous cannabinoids, such as Δ^9 -tetrahydrocannabinol, the
22 main active principle of cannabis, the synthetic cannabinoid receptor ligand WIN55212-2 and the
23 endocannabinoid arachidonylethanolamide (anandamide, AEA), in studies performed in animals
24 and humans.²² The IOP-lowering effect exerted by topical AEA was counteracted by concomitant
25 administration of the CB₁ receptor antagonist SR141716A (rimonabant), supporting a role for this
26 receptor in the modulation of IOP.²³ However, cannabinoid actions on IOP are also mediated by
27 other, CB₁-independent, mechanisms such as activation of the TRPV1 channel and the orphan
28 receptor GPR55 and by arachidonic acid-based COX products.²⁴ Experimental findings suggest that
29 the endocannabinoid system participates to the control of IOP modulating both production and
30 outflow of aqueous humor. The serine-hydrolase enzyme fatty acid amide hydrolase (FAAH) is the
31 main AEA-degrading enzyme.^{25,26} FAAH is also responsible for the hydrolysis of several other fatty
32 acid ethanolamides (FAEs) which have been found in the eye and might contribute to the regulation
33 of IOP through specific mechanisms. Interestingly, FAAH has been described as responsible for the
34 regulation of diurnal variation of IOP. In fact, FAAH is expressed with a circadian rhythm and high
35 FAAH levels drive the production of N-arachidonoyl glycine which reduces IOP by activating
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 GPR18 receptor.²⁷ However, despite the relevance of FAAH on IOP modulation, the effect of
4
5 FAAH inhibitors on IOP has never been described.

6
7 In this study, we report the design of novel dual-acting compounds that behave as MLT receptor
8
9 agonists and FAAH inhibitors, and their evaluation as IOP lowering agents. We combined the
10
11 pharmacophore elements required for activation of melatonergic receptors with those for FAAH
12
13 inhibition, exploiting the relevant structural elements of two well-known classes of compounds. In
14
15 particular, N-anilinoethylamides (Figure 2) are a class of versatile melatonergic ligands in which
16
17 modulations of substituents at the aniline nitrogen and on benzene ring have allowed fine tuning of
18
19 binding affinity, receptor subtype selectivity and intrinsic activity.^{28,29} The benzene ring of the
20
21 aniline structure tolerates bulky, lipophilic alkyloxy substituents, which can also provide some
22
23 selectivity for the MT₁ receptor.³⁰ On the other hand, N-alkyl-O-arylcarbamates are widely used
24
25 FAAH inhibitors which irreversibly carbamoylate the catalytic serine residue.³¹ A representative
26
27 compound from this class, URB597 (**2**, Figure 1), has become the reference FAAH inhibitor in
28
29 pharmacological studies investigating the physio-pathological roles of this enzyme and its
30
31 substrates.³² We devised therefore two new series of N-anilinoethylamide derivatives carrying on
32
33 the aniline ring an alkoxy linker bound to a carbamoyl portion, intended to exert FAAH inhibition
34
35 (Figure 2). In one series, an N-cyclohexyl-O-phenylcarbamate portion was joined to the aniline O-
36
37 alkyl side chain through a second bridging oxygen atom. In a second series, the cyclohexyl
38
39 substituent of URB597 was replaced by the alkyl chain stemming from the aniline portion of
40
41 melatonergic ligands, as known structure-activity relationships for O-aryl-N-alkyl carbamates had
42
43 evidenced that a linear alkyl chain is tolerated without significantly affecting FAAH inhibitory
44
45 potency.³¹ The length of the alkyl spacer and the substitution patterns were previously investigated
46
47 by molecular modelling, docking the modelled compounds within their putative binding sites at the
48
49 two protein targets. While for FAAH several crystal structures are available, for MLT receptors a
50
51 homology-based model of the MT₁ subtype was employed. As the second series of compounds
52
53
54
55
56
57
58
59
60

1
2
3 resulted the most promising one at preliminary biological tests, it was further explored replacing the
4
5 N-anilinoethylamide portion with the original indole structure of melatonin (Figure 2).

6
7 The compounds were tested on human MT₁ and MT₂ receptors to evaluate their binding affinity and
8
9 intrinsic activity, on rat FAAH for their inhibitory potency and in a rabbit model of ocular
10
11 hypertension to investigate their IOP-lowering potential.
12



46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2. Design of dual-acting compounds by combination of relevant structural features of N-anilinoethylamide melatonergic ligands and N-alkyl-O-arylcarbamate FAAH inhibitors.

Chemistry


Compounds **10-13** (Scheme 1) were obtained by O-alkylation of (3-hydroxyanilinoethyl)amides (**5a-b**) with the bromoalkylphenoxy derivative **6** or **7** (which in turn were prepared by O-alkylation of 3-(benzyloxy)phenol with the proper dibromoalkane) in the presence of NaH, followed by O-debenzylation by hydrogenolysis (**10-11**) and subsequent O-carbamoylation with *c*-hexylisocyanate in the presence of Et₃N (**12-13**). The key intermediates **5a-b** were synthesized according to a well-

1
2
3 validated route to similar compounds,³³ involving a reductive N-alkylation of 3-methoxy-*N*-
4 methylaniline with the suitable *N*-acylaminoacetaldehyde dimethyl acetal (**3a,b**) in the presence of
5 TFA/Et₃SiH, followed by methyl ether cleavage of intermediates **4a,b** using boron tribromide.

6
7
8
9 Compounds **20a-e** and **20g** were prepared in a convergent fashion following the steps outlined in
10 Scheme 2. First, the aminoalkoxyphenyl intermediates **16a-d** were synthesized by O-alkylation of
11 the previously cited phenol derivatives **5a,b** with the appropriate *tert*-butyl (ω -
12 bromoalkyl)carbamate **14a-c** in the presence of K₂CO₃/NaI and subsequent *N*-Boc-deprotection
13 (TFA). The activated carbonates **19d-f** were then prepared by reaction of 1,1-biphenyl-3-ol
14 derivatives (**18d-f**) [commercially available (**18d**) or prepared by a Suzuki coupling reaction of 3-
15 bromophenol with the suitable phenylboronic acid **17e-f**] with *p*-nitrophenyl chloroformate in the
16 presence of *N,N*-diisopropylethylamine (DIPEA). Finally, carbamates **20a-f** were obtained by the
17 convergent coupling of the aminoalkoxyphenyl intermediates **16a-d** with the appropriate 4-
18 nitrophenyl carbonate (**19d-f**). The final compound **20g** was achieved by hydrogenolysis of the
19 benzyloxy precursor **20f**.


20
21
22
23
24
25
26
27
28
29
30
31
32
33 Compounds **27-29** were obtained by condensation of 5-(aminoalkoxy)-*N*-acetyltryptamines **24-26**
34 with the (4-nitrophenyl)carbonate derivative **19d** as outlined in Scheme 3. The intermediate amines
35 **24-25** were prepared by O-alkylation of *N*-acetylserotonin with *tert*-butyl (6-bromohexyl)carbamate
36 (**14b**) or *tert*-butyl (8-bromooctyl)carbamate (**14c**) in the presence of K₂CO₃, and subsequent *N*-Boc
37 deprotection with trimethylsilyl bromide. The 2-bromoindole derivative **23** was obtained by
38 bromination of **21** with trimethylphenylammonium tribromide in THF, before submitting it to *N*-
39 Boc deprotection to give **26**.

40
41
42
43
44
45
46
47
48
49
50 **Scheme 1^a**




^aReagents and conditions: a) (RCO)₂O, Et₃N, CH₂Cl₂, rt, 2 h, yield 90-93%; b) 3-methoxy-*N*-methylaniline, Et₃SiH, TFA, CH₂Cl₂, rt, 20 h, yield 51-52%; c) BBr₃, CH₂Cl₂, 0 °C to rt, 20 h, yield 68-76%; d) K₂CO₃, acetone, 50 °C, 24 h, yield 68-82%; e) NaH, DMF, -10 °C to rt, 16 h, yield 85-89%; f) H₂ (1 atm), 10% Pd-C, EtOH/EtOAc, rt, 16 h, yield 78-92%; g) Et₃N, EtOH/ CH₃CN, rt, 18 h, yield 65-95%.

Scheme 2^a



^aReagents and conditions: a) K₂CO₃, NaI, acetone, 60 °C, 24 h, yield 20-44%; b) TFA, CH₂Cl₂, rt, 16 h, yield 60-64%; c) for **18e** Pd(PPh₃)₄, Na₂CO₃, CH₃CN, 90 °C, 1.5 h, yield 97%; d) for **18f** Pd(OAc)₂, Na₂CO₃, H₂O, acetone, 35 °C, 40 min, yield 81%; e) DIPEA, CH₃CN, rt, 1 h, yield 47-74%; f) Et₃N, CH₂Cl₂, rt, 4 h, yield 38-90%; g) H₂ (1 atm), 10% Pd-C, EtOH/EtOAc, rt, 20 h, yield 76%.

Scheme 3^a



"Reagents and conditions: a) K_2CO_3 , NaI, CH_3CN , reflux, 20 h, yield 47-59%; b) $(CH_3)_3N(Br_3)C_6H_5$, THF, rt, 30 min, yield 59%; c) CH_3CN , rt, 1 h; d) Et_3N , CH_2Cl_2/DMF , rt, 3 h, two steps (c, d) yield 83-95%.

Results and discussion

Design of new compounds

The accommodation of putative dual-acting agents into MLT receptor binding site and FAAH catalytic pocket was previously evaluated by docking simulations. Due to the lack of crystal structures of MLT receptors, docking studies were performed within a homology model of the MT_1 receptor in its active conformation previously developed and tested by us.³⁰ Preceding docking models for melatonergic ligands had proposed that substituent originating from the aromatic oxygen

1
2
3 atom (e.g., the methoxy oxygen of MLT), which is important for receptor affinity, can be
4
5 accommodated within a lipophilic channel outlined by transmembrane (TM) helices 3, 4 and 5,
6
7 open toward the extracellular space in its upper portion. The presence of some smaller amino acids
8
9 lining this channel in the MT₁ receptor subtype, compared to the corresponding residues in the MT₂
10
11 subtype, has been proposed as the structural element conferring MT₁ selectivity to ligands with
12
13 bulkier substituents at the oxygen atom (e.g., a phenylbutyl group).³⁰ Since both of these MLT
14
15 receptor subtypes have been implicated in the ocular hypotensive activity observed for MLT
16
17 agonists,^{15,34} in order to obtain compounds with similar activity at MT₁ and MT₂ receptors an alkyl
18
19 linker was inserted to connect the MLT receptor binding portion to the FAAH inhibiting one, with
20
21 the idea that the slim alkyl chain could be tolerated into both receptors, allowing the carbamate
22
23 portion to interact with the extracellular region of the receptor. Docking models showed that both
24
25 orientations of the carbamate portion, corresponding to the two series of compounds **12-13** and **20**,
26
27 could be accommodated in the extracellular lobby, provided that at least four-methylene long
28
29 spacers were inserted. The binding pose into the MT₁ receptor obtained for compound **20e**, which
30
31 has a six-methylene spacer, is represented in Figure 3, where the bulkier amino acids lining the
32
33 lipophilic channel of the MT₂ receptor are also shown. The carbamoyl fragment of **20e** protrudes
34
35 out of the TM portion of the receptor and interacts with amino acids belonging to extracellular loop
36
37 2. The N-anilinoethylamide portion undertakes the pattern of interactions already proposed for
38
39 melatonergic ligands, comprising hydrogen bonds between Tyr285 in TM7 and the amide oxygen
40
41 and between Tyr187 in TM5 and the alkoxy oxygen.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 3. Induced-fit docking solution obtained for compound **20e** into the homology model³⁰ of the MT₁ receptor. Side chains of bulkier amino acids belonging to the MT₂ receptor are represented in shaded green (MT₁: Gly104^{3,29}, Val159^{4,57}, Leu163^{4,61}; MT₂: Ala117^{3,29}, Leu172^{4,57}, Phe176^{4,61}).

Fitting of dual-acting compounds into the active site of FAAH was also evaluated. Compounds belonging to the N-cyclohexyl-O-phenylcarbamate series, exemplified by compound **13** in Figure 4 (left), place their cyclohexyl ring in the acyl chain binding (ACB) channel, consistent with its location in the crystal structure of FAAH carbamoylated by URB597.³⁵ The long substituent at carbamate oxygen atom occupies the cytoplasmic access (CA) channel taking polar interactions with Lys263 and Gln273. The lower FAAH-inhibitory potency observed for this series (see below) was attributed to possible repulsive interaction of the anilinoethylamide fragment with the dimer interface of FAAH which could be detrimental for compound affinity.

The second class of compounds (**20a-d**) generally gave docking solutions placing the melatonergic portion within the ACB channel, which looked more tolerant to structural alternatives. For this reason, and because preliminary data indicated this class as more promising than the first one, structural variants were introduced while conserving the O-biphenyl-3-yl-carbamate scaffold. In particular, small polar groups were introduced at the 3' position of the biphenyl nucleus (**20e**, **20g**), trying to improve FAAH inhibitory potency and the length of the spacer was increased to eight

1
2
3 methylenes (**20c**) to exploit the steric tolerance of the ACB channel of FAAH. At the melatonergic
4
5 portion, the acetylamino group was replaced by a propionylamino one (**20b**) and the N-
6
7 anilinoethylamide scaffold by the N-indolyethylamide one of MLT to favour interactions at the
8
9 melatomegic receptors. A representation of the docking solution obtained for the bulkiest inhibitor
10
11 **29** is provided in Figure 4 (right). The carbamate portion occupies the catalytic site and its NH
12
13 group is hydrogen-bonded to the carbonyl oxygen of Met191. The carbamate oxygen is stabilized
14
15 into the oxyanion hole, interacting with the backbone NH groups of Ile238 and Gly239. The
16
17 biphenyl portion is accommodated into the CA channel, while the long substituent at carbamate
18
19 nitrogen extends inside the ACB channel. The bulky 2-bromolindole terminal portion of **29** has
20
21 room enough to be properly accommodated: while the acetylamide takes a hydrogen bond with
22
23 Thr488, the bromine atom fits into a lipophilic pocket lined by amino acids Ala377, Leu380,
24
25 Phe381 and Phe432.




44 **Figure 4.** Compounds **13** (left) and **29** (right) docked into FAAH substrate binding site (PDB ID:
45 1MT5). Gray ribbons and surfaces refer to the monomer of FAAH which includes the catalytic site
46
47 were inhibitors were docked; orange ribbons and surfaces refer to the other FAAH monomer
48
49 associated with the first one. Docked inhibitors are represented with yellow (**13**) or green (**29**)
50
51 carbons.
52
53
54
55
56
57
58
59
60

In vitro potency and structure-activity relationships

Binding affinity and intrinsic activity at MT₁ and MT₂ receptors and FAAH inhibitory potency obtained for the newly synthesized compounds are reported in Table 1.

Table 1. Binding Affinity and Intrinsic Activity of Newly Synthesized Compounds at Human Melatonin Receptors MT₁ and MT₂ and Inhibition Potency (IC₅₀) of Rat FAAH Activity.



Cmpd	MLT receptors				rFAAH			
	n	R	R ¹	hMT ₁		hMT ₂		
				pK _i ± SD ^a	IA _r ± SD ^b	pK _i ± SD ^a	IA _r ± SD ^b	IC ₅₀ (nM) ± SEM ^c
1 MLT				9.69 ± 0.09	1.00 ± 0.01	9.54 ± 0.06	1.00 ± 0.03	nd ^d
2 URB5 97				nd	nd	nd	nd	4.6 ± 1.6 ^e
10	4	-	-	6.73 ± 0.08	0.27 ± 0.07	6.22 ± 0.07	0.18 ± 0.09	nd
11	6	-	-	7.23 ± 0.11	0.62 ± 0.14	6.48 ± 0.04	0.57 ± 0.08	nd
12	4	-	-	7.46 ± 0.10	0.07 ± 0.07	7.27 ± 0.01	0.05 ± 0.05	184±3
13	6	-	-	7.56 ± 0.09	0.71 ± 0.04	6.53 ± 0.06	0.71 ± 0.05	197±6

16a	4	-	-	5.51 ± 0.08	0.32 ± 0.09	4.89 ± 0.50	0.35 ± 0.04	nd
16d	6	-	-	6.35 ± 0.03	0.34 ± 0.05	6.40 ± 0.04	0.08 ± 0.01	nd
20a	4	H	CH ₃	7.89 ± 0.03	0.64 ± 0.07	7.35 ± 0.03	0.39 ± 0.07	1.45±0.01
20b	6	H	CH ₂ CH ₃	7.79 ± 0.04	0.77 ± 0.08	7.72 ± 0.02	0.88 ± 0.02	3.07±0.08
20c	8	H	CH ₃	7.50 ± 0.01	0.85 ± 0.08	7.49 ± 0.02	0.96 ± 0.03	0.63±0.04
20d	6	H	CH ₃	7.67 ± 0.01	0.70 ± 0.01	7.48 ± 0.02	0.75 ± 0.03	1.34±0.03
20e	6	CONH ₂	CH ₃	7.41 ± 0.03	0.79 ± 0.06	7.81 ± 0.05	1.01 ± 0.02	0.43±0.01
20g	6	OH	CH ₃	7.53 ± 0.02	0.89 ± 0.08	7.57 ± 0.01	0.94 ± 0.02	0.36±0.01
27	6	H	-	8.22 ± 0.01	0.73 ± 0.08	8.34 ± 0.09	1.02 ± 0.02	2.38±0.16
28	8	H	-	8.31 ± 0.70	0.73 ± 0.08	8.20 ± 0.02	0.53 ± 0.02	4.00±0.10
29	6	Br	-	9.11 ± 0.10	0.73 ± 0.08	8.77 ± 0.03	0.97 ± 0.02	0.85±0.01

^a p*K*_i values were calculated from IC₅₀ values, obtained from competition curves by the method of Cheng and Prusoff,³⁶ and are the mean of at least three determinations performed in duplicate. ^b The relative intrinsic activity values were obtained by dividing the maximum analogue-induced G-protein activation by that of MLT. Measurements were performed in triplicate. ^c IC₅₀ values are the mean of at least two determinations. ^d nd: not determined. ^e Ref. 32.

N-Cyclohexylcarbamic acid O-phenyl esters **12** and **13** showed only moderate binding affinity at human MT₁ and MT₂ receptors, about one hundred times lower than that of MLT. These compounds, as well as all the other agents in Table 1, showed no receptor subtype selectivity, consistent with our design strategy. Compounds **10** and **11**, which could be produced in vivo from hydrolysis of carbamates **12** and **13**, showed reduced binding affinity, that may be attributed to lower lipophilicity of their chains. In fact, the detrimental role played by hydrophilic substituents on the side chain stemming from the *meta*-oxygen of N-anilinoethylamide derivatives has already been observed.³⁷ Compounds **12** and **13** also showed poor potency on FAAH. Compared to the biphenyl

1
2
3 substituent of compound **2** the longer phenoxyalkyl chain significantly impacted on the ability to
4
5 inhibit enzyme activity.

6
7 O-biphenylcarbamates **20a-e**, **20g** showed binding affinities at MT₁ and MT₂ receptors similar or
8
9 slightly higher than the previous N-cyclohexylcarbamates **12** and **13**. The length of the alkyl spacer
10
11 did not influence binding affinity and similar potencies were observed for compounds **20a** and **20d**,
12
13 and for the longest compound **20c**. However, chain lengthening was correlated with an increase in
14
15 intrinsic activity, with compound **20c** behaving as an agonist. Also the replacement of the
16
17 acetylamino group of **20d** with a propionylamino one (**20b**) produced the expected slight increase in
18
19 binding affinity and intrinsic activity, consistent with SAR profile of melatonergic ligands.^{11,29}

20
21 These compounds showed remarkable ability to inhibit FAAH activity, with a subnanomolar IC₅₀
22
23 value observed for compound **20c**. Substituents known to be accommodated in FAAH active site
24
25 were inserted in meta position of the distal phenyl ring.³² As expected, the aminocarbonyl and
26
27 hydroxyl derivatives **20e** and **20g** showed improved potencies compared to the unsubstituted **20d**.
28
29 These substituents were tolerated at MLT receptors and led to an increase of intrinsic activity at
30
31 both receptor subtypes. MT₁ and MT₂ binding affinity of the amino derivatives **16a** and **16d**,
32
33 formally deriving from carbamate hydrolysis was also tested. Consistently with the previously cited
34
35 SAR for N-anilinoethylamide ligands, no significant affinity could be measured for these basic and
36
37 hydrophilic derivatives. Therefore activity of O-biphenyl carbamates at MLT receptors has to be
38
39 ascribed to the compounds *per se*, and not to metabolites deriving from hydrolysis reactions
40
41 performed by FAAH or other hydrolases.

42
43
44
45
46 O-Biphenylcarbamates demonstrated that it is possible to fuse the structural elements required for
47
48 FAAH inhibition and for MLT receptor binding and activation in the same molecule. However,
49
50 activity at the two targets of compounds **20a-e** and **20g** appeared rather unbalanced as FAAH
51
52 inhibitory potency is about 10-100 times higher than binding affinity at MLT receptors. To increase
53
54 MT₁ and MT₂ binding affinity the N-anilinoethylamide portion was replaced by the N-
55
56 indolyethylamide scaffold of MLT. This bioisosteric replacement allowed to increase MLT
57
58
59
60

1
2
3 receptor binding affinity of about one order of magnitude as observed for compounds **27** and **28**,
4
5 with maintenance of FAAH inhibitory potency in the nanomolar range. Moreover, introduction of a
6
7 bromine atom in position 2 of the indole ring in compound **29** allowed a further increase of MT₁
8
9 and MT₂ binding affinity, consistent with SAR for indole derivatives.³⁸ The bromine atom slightly
10
11 improved FAAH inhibitory potency leading to a subnanomolar IC₅₀ value, consistent with our
12
13 hypothesis that this substituent can be favorably positioned in the lipophilic acyl chain binding
14
15 pocket of FAAH (see previous modelling paragraph). Compound **29** represents therefore a potent
16
17 dual-acting melatonergic agonist and FAAH inhibitor with balanced potency at the two targets.
18
19

22 **Ocular pressure lowering activity**

23
24 The ability to reduce IOP of compounds belonging to the two most active series, **20c,e,g** carrying an
25
26 N-anilinoethylamide portion and **27-29**, with an N-indolyethylamide one, was evaluated *in vivo* in
27
28 an animal model of glaucoma. Their behavior was compared with that of compounds **1** and **2** and of
29
30 the clinically used IOP lowering agent dorzolamide (**30**). 50 µL of a solution of the test compounds
31
32 at 1 mM concentration were topically administered into the lower conjunctival pocket to male New
33
34 Zealand albino rabbits with elevated IOP, induced by the injection of 0.1 mL of sterile hypertonic
35
36 saline solution (5% in distilled water) into the vitreous body. Reference compound **30** was tested at
37
38 1% concentration (w/v) of dorzolamide hydrochloride. IOP was measured 60, 120 and 240 min
39
40 after pressure stabilization following hypertonic saline injection.
41
42

43
44 Efficacy of compounds was monitored after 60 and 120 min, as after 4 hours IOP was returned to
45
46 basal, pre-injection values (Figure 5). Compound **1** had a prompt effect, visible at 60 min which
47
48 was maintained also at 120 min, even if with lower efficacy. A similar behavior was observed for
49
50 the reference FAAH inhibitor **2**. Reduction of IOP by cannabinoid receptor ligands, both
51
52 endocannabinoids and synthetic compounds, had been widely described, but this is the first time
53
54 that efficacy as an IOP lowering agent is reported for a compound which acts indirectly, by
55
56 increasing the local availability of anandamide and other fatty acid ethanolamides. Co-
57
58
59

administration of compounds **1** and **2**, both at 1mM concentration, produced the same effect as the administration of single agents at 60 min. However, the IOP reduction was maintained at 120 min, while single agents **1** and **2** lost part of their efficacy at this time. The carbonic anhydrase inhibitor **30** had a prompt effect, similar to that of compounds **1** and **2** at 60 min, which is maintained at 120 min as well. The N-anilinoethylamide derivatives **20c**, **20e** and **20g** behaved similarly, showing limited effect after 60 min, which significantly increased at 120 min, exceeding those measured for compounds **1** and **2**. In the N-indolyethylamide series (**27-29**) compounds **27** and **28** were relatively active at 60 min, with limited activity at longer times. On the other hand, compound **29** had significantly improved efficacy at 120 min, in analogy with compounds from the **20** series. In fact, it provided the highest IOP reduction at 120 min which is also partly maintained at 240 min.




Figure 5. Drop of intraocular pressure (Δ IOP, mm Hg) versus time (min) in hypertonic saline-induced ocular hypertension in New Zealand male albino rabbits measured for compounds **1** (melatonin), **2** (URB597), the combination of compounds **1** and **2**, the reference inhibitor **30** (dorzolamide) and dual-acting inhibitors **20c**, **20e**, **20g**, **27**, **28** and **29**, tested at 1 mM concentration

(compound **30** tested at 1% (w/v) concentration). Histograms represent Δ IOP change, i.e., the mean difference (n= 4 for each treatment group) in Δ IOP between the eye treated with vehicle and the contralateral one, treated with the drug. Positive values mean that drug-treated eyes have lower IOP than vehicle-treated ones. Error bars represent s.e.m. of mean IOP value (n=4). Tabular data of Δ IOP can be found in Supplementary Table S3. Data are analyzed with 2way Anova followed by Bonferroni multiple comparison test. $p < 0.05$ was used to identify statistical significance. * $p < 0.05$: **1**, **2** and **30** vs vehicle at 60 min; **20c** vs vehicle at 120 min; **29** vs **2** at 120 min. ** $p < 0.01$: **30** vs vehicle at 120 min; **29** vs **1** at 120'. *** $p < 0.001$: **20e** and **29** vs vehicle at 120 min.

Discussion and conclusions

Novel compounds targeting two physiological systems involved in the control of IOP were devised. Exploitation of SAR for melatonin receptor agonists and carbamate FAAH inhibitors led to dual-acting agents with remarkable and balanced activity at both targets. In the rabbit model of high IOP compounds were more effective at longer times (120 min) compared to reference single-acting agents **1**, **2** and the most potent derivatives **20e** and **29** were more effective than the therapeutic agent **30**. This behavior might be due either to the synergistic effect at the two targets or to the higher lipophilicity of the dual-acting compounds, which could assure a longer residence time at the site of action. Combination of compounds **1** and **2** gave the same effect as single agents at 60 min, thus showing no additivity, but this effect was maintained at longer times (120 min). Thus, only the combination of the two gave a time profile similar to that of dorzolamide (**30**). As for dual-acting compounds, the N-anilinoethylamide **20e** and the N-indolyethylamide **29** gave the best IOP lowering effect at 120 min, comparable or better than dorzolamide (**30**). Comparing in vivo with in vitro activity, the ability of dual-acting compounds to reduce IOP at longer times seems to be strictly related to their potency as FAAH inhibitors. In fact, the compounds most active at 120 min (**20c**, **20e**, **20g** and **29**) showed sub-nM IC_{50} values on FAAH, while compounds **27** and **28** had

1
2
3 lower FAAH inhibitory potency. On the other hand, compound **29** having the highest efficacy at
4 longer times (120 and 240 min) is endowed with high potency on both targets. Therefore, the
5 combination of high melatonergic activity with potent inhibition of FAAH appears as a requisite to
6 obtain a significant and persistent IOP lowering effect, even if a role for physicochemical
7 properties, such as compound lipophilicity, cannot be ruled out.
8

9
10
11
12
13 These compounds represent a potential alternative therapeutic approach for the treatment of ocular
14 hypertension and might offer a promising option for the treatment of glaucoma in light of their
15 potential neuroprotective effect. In fact, the endocannabinoid system is involved in cell survival
16 mechanisms of RGC³⁹ and endocannabinoids and FAAH inhibitors have been described as able to
17 minimize the retinal damage and reduce RGC loss in a model of high intraocular pressure-induced
18 ischemia.⁴⁰ On the other hand, the neuroprotective activity of melatonin is widely known and its
19 protective role has been demonstrated also in ocular tissues.⁹ A neuroprotective role has been
20 described also for synthetic melatonin receptor ligands. In addition, reduction of RGC death may
21 positively modulate pineal melatonin production that could improve circadian rhythm-related
22 functions, thus ameliorating conditions often present in glaucomatous patients such as sleep
23 disorders and depression.⁴¹
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **Experimental section**

43 **General procedures**

44
45 Melting points were determined on a Buchi B-540 capillary melting point apparatus and are
46 uncorrected. ¹H NMR and ¹³C NMR spectra were recorded on a Bruker AVANCE 400 instrument,
47 using CDCl₃ as solvent unless stated otherwise. Chemical shifts (δ scale) are reported in parts per
48 million (ppm) relative to the central peak of the solvent. Coupling constants (*J*) are given in hertz
49 (Hz). ESI MS spectra were taken on a Waters Micromass ZQ instrument; molecular ions [M+1]⁺ or
50 [M-1]⁻ are given. High-resolution mass spectroscopy was performed on a Micromass Q-ToF Micro
51
52
53
54
55
56
57
58
59
60

1
2
3 mass spectrometer (Micromass, Manchester, UK) using an ESI source. The purity of all tested
4
5 compounds, determined by LC-MS using a Waters HPLC/UV/MS system (separation module
6
7 Alliance HT2795, Photo Diode Array Detector 2996, mass detector Micromass ZQ; software:
8
9 MassLynx 4.1), was greater than 95% (see Supporting Information). Column chromatography
10
11 purifications were performed under “flash” conditions using Merck 230–400 mesh silica gel.
12
13 Analytical thin-layer chromatography (TLC) was carried out on Merck silica gel 60 F₂₅₄ plates. *tert*-
14
15 Butyl (4-bromobutyl)carbamate, *tert*-butyl (6-bromohexyl)carbamate, [1,1'-biphenyl]-3-ol, (3-
16
17 carbamoylphenyl)boronic acid, [3-(benzyloxy)phenyl]boronic acid, 3-(benzyloxy)phenol, 2,2-
18
19 dimethoxyethanamine and *N*-acetylserotonin were purchased from commercial suppliers and used
20
21 without further purification.
22
23
24
25

26 **General Procedure for the synthesis of *N*-(2,2-Dimethoxyethyl)acylamines 3a,b.** Acetic or
27
28 propionic anhydride (12 mmol) and Et₃N (1.65 mL, 12 mmol) were added to a solution of 2,2-
29
30 dimethoxyethanamine (1.08 mL, 10 mmol) in dry CH₂Cl₂ (16 mL) and the resulting mixture was
31
32 stirred at room temperature for 2 h. The mixture was neutralized with a saturated solution of
33
34 NaHCO₃ and extracted with CH₂Cl₂. The combined organic phases were washed with brine, dried
35
36 (Na₂SO₄), filtered and concentrated in vacuo affording a crude residue that was purified by silica
37
38 gel column chromatography.
39
40
41
42

43 ***N*-(2,2-Dimethoxyethyl)acetamide (3a).** Flash chromatography (CH₂Cl₂-MeOH 98:2 as eluent).
44
45 Oil; 90% yield. Chemical physical data were identical to those previously reported.³³
46
47
48
49

50 ***N*-(2,2-Dimethoxyethyl)propionamide (3b).** Flash chromatography (CH₂Cl₂-EtOAc 95:5 as
51
52 eluent). Oil; 93% yield. ¹H NMR (CDCl₃) δ: 1.16 (t, 3H, *J* = 7.5), 2.23 (q, 2H, *J* = 7.5), 3.40 (s,
53
54 6H), 3.39-3.44 (m, 2H), 4.38 (t, 1H, *J* = 5.0), 5.70 (brs, 1H). ESI MS (*m/z*): 184 [M+Na]⁺.
55
56
57
58
59
60

1
2
3 **General Procedure for the synthesis of (anilinoethyl)amido derivatives 4a,b.** Trifluoroacetic
4 acid (2.2 mL, 29 mmol) and triethylsilane (0.9 mL, 5.6 mmol) were added to a solution of 3-
5 methoxy-*N*-methylaniline (0.3 mL, 2.3 mmol) and the suitable acetal **3a,b** (3.1 mmol) in CH₂Cl₂ (5
6 mL), and the resulting mixture was stirred at room temperature for 20 h under a nitrogen
7 atmosphere. After cooling to 0 °C, the mixture was carefully neutralized with a saturated aqueous
8 solution of NaHCO₃ and the aqueous layer was extracted with CH₂Cl₂. The combined organic
9 phases were washed with brine, dried over Na₂SO₄ and concentrated under reduce pressure to give a
10 crude residue that was purified by column chromatography.
11
12
13
14
15
16
17
18
19
20
21

22 ***N*-{2-[(3-Methoxyphenyl)methylamino]ethyl}acetamide (4a).** Purification by silica gel flash
23 chromatography (EtOAc as eluent) and crystallization. White solid (diethyl ether/petroleum ether),
24 51% yield. Chemical physical data were identical to those previously reported.³³
25
26
27
28
29
30

31 ***N*-{2-[(3-Methoxyphenyl)methylamino]ethyl}propionamide (4b).** Purification by silica gel
32 chromatography (EtOAc-cyclohexane 7:3 as eluent). Oil, 52% yield. ¹H NMR (CDCl₃) δ: 1.12 (t,
33 3H, *J* = 7.5), 2.16 (q, 2H, *J* = 7.5), 2.95 (s, 3H), 3.46-3.47 (m, 4H), 3.80 (s, 3H), 5.70 (brs, 1H),
34 6.31-6.33 (m, 2H), 6.42 (dd, 1H, *J* = 2.0 and 8.0), 7.16 (dd, 1H, *J*₁ = *J*₂ = 8.5). ¹³C NMR (CDCl₃) δ:
35 174.0, 160.9, 150.6, 130.0, 105.8, 102.1, 99.3, 55.2, 52.0, 38.6, 37.2, 29.6, 9.7. ESI MS (*m/z*): 237
36 [M+H]⁺.
37
38
39
40
41
42
43
44
45

46 **General Procedure for the synthesis of (3-hydroxyanilino)ethylamido derivatives 5a,b.** A 1M
47 solution of BBr₃ in CH₂Cl₂ (2.5 mL, 2.5 mmol) diluted with dry CH₂Cl₂ (9 mL) was added
48 dropwise to an ice-cooled solution of the suitable amide **4a,b** (1.23 mmol) in dry CH₂Cl₂ (9 mL)
49 and the resulting mixture was stirred at room temperature for 20 h. After neutralization with a 2N
50 aqueous solution of Na₂CO₃, the mixture was extracted with CH₂Cl₂, and the combined organic
51
52
53
54
55
56
57
58
59
60

1
2
3 phases were dried (Na_2SO_4) and concentrated under reduced pressure to give a crude residue that
4
5 was purified by column chromatography.
6
7

8
9 ***N*-{2-[(3-Hydroxyphenyl)methylamino]ethyl}acetamide (5a)**. Purification by silica gel flash
10 chromatography (CH_2Cl_2 -MeOH 98:2 as eluent). Oil, 76% yield. Chemical physical data were
11 identical to those previously reported.³⁰
12
13
14

15
16
17
18 ***N*-{2-[(3-Hydroxyphenyl)methylamino]ethyl}propionamide (5b)**. Purification by silica gel
19 chromatography (EtOAc-cyclohexane 7:3 as eluent). Oil, 68% yield. ^1H NMR (CDCl_3) δ : 1.13 (t,
20 3H, $J = 7.5$), 2.18 (q, 2H, $J = 7.5$), 2.94 (s, 3H), 3.45-3.47 (m, 4H), 5.71 (brs, 1H), 6.01 (brs, 1H),
21 6.25 (d, 1H, $J = 7.5$), 6.32-6.36 (m, 2H), 7.09 (dd, 1H, $J_1 = J_2 = 8.0$). ESI MS (m/z): 223 [$\text{M}+\text{H}$]⁺.
22
23
24
25
26
27

28 **General Procedure for the synthesis of bromoalkylphenoxy derivatives 6 and 7**. K_2CO_3 (0.31 g,
29 2.25 mmol) and the suitable dibromoalkane (2.25 mmol) were added to a solution of 3-
30 (benzyloxy)phenol (0.3 g, 1.5 mmol) in dry acetone (4 mL), and the resulting mixture was stirred at
31 50°C for 24 h. After addition of water the mixture was extracted with EtOAc and the combined
32 organic phases were dried (Na_2SO_4). After removing the solvent by distillation under reduced
33 pressure, the crude residue was purified by silica gel column chromatography (cyclohexane-EtOAc
34 95:5 as eluent).
35
36
37
38
39
40
41
42
43
44
45

46 **1-(Benzyloxy)-3-(4-bromobutyloxy)benzene (6)**. Oil, 68% yield. Analytical data were in
47 agreement to those previously reported.⁴²
48
49
50
51

52 **1-(Benzyloxy)-3-(6-bromohexyloxy)benzene (7)**. Oil, 82% yield. ^1H NMR (CDCl_3) δ : 1.49-1.56
53 (m, 4H), 1.81-1.92 (m, 4H), 3.45 (t, 2H, $J = 6.5$ Hz), 3.96 (t, 2H, $J = 6.5$ Hz), 5.07 (s, 2H), 6.58-
54 6.62 (m, 3H), 7.19 (dd, 1H, $J_1 = J_2 = 8.0$ Hz), 7.28-7.45 (m, 5H); ^{13}C NMR (CDCl_3) δ : 160.3, 160.0,
55
56
57
58
59
60

1
2
3 137.0, 129.9, 128.6, 128.0, 127.5, 107.1, 106.9, 101.8, 70.0, 67.7, 33.9, 32.7, 29.1, 27.9, 25.3. ESI
4 MS (*m/z*): 363-365 [M+H]⁺.
5
6
7
8

9 **General Procedure for the synthesis of derivatives 8 and 9.** NaH (60% in mineral oil, 0.026 g,
10 0.65 mmol) was added to a solution of **5a** (0.13 g, 0.63 mmol) in dry DMF (1 mL) and the resulting
11 mixture was stirred at -10 °C for 10 min under a nitrogen atmosphere. Then a solution of the
12 suitable bromoalkylphenoxy derivative **6** or **7** (0.65 mmol) in dry DMF (1.5 mL) was added and the
13 resulting mixture was stirred at room temperature for 16 h. After addition of water the mixture was
14 extracted with EtOAc, the combined organic phases were dried (Na₂SO₄), filtered and concentrated
15 under reduced pressure to afford a crude product that was purified by silica gel column
16 chromatography (EtOAc as eluent).
17
18
19
20
21
22
23
24
25
26
27

28 ***N*-[2-({3-[4-(3-Benzoyloxy)phenoxy]butoxy}phenyl)methylaminoethyl]acetamide (8).** Oil, 89%
29 yield. ¹H NMR (CDCl₃) δ: 1.94 (s, 3H), 1.94-1.98 (m, 4H), 2.94 (s, 3H), 3.45-3.47 (m, 4H), 3.98-
30 4.09 (m, 4H), 5.05 (s, 2H), 5.61 (brs, 1H), 6.27-6.43 (m, 3H), 6.51-6.60 (m, 3H), 7.10-7.23 (m, 2H),
31 7.32-7.46 (m, 5H). ESI MS (*m/z*): 463 [M+H]⁺.
32
33
34
35
36
37
38

39 ***N*-{2-([3-[6-(3-Benzoyloxy)phenoxy]hexyloxy]phenyl(methylamino)ethyl}acetamide (9).** Oil,
40 85% yield. ¹H NMR (CDCl₃) δ: 1.50-1.57 (m, 4H), 1.75-1.90 (m, 4H), 1.94 (s, 3H), 2.93 (s, 3H),
41 3.44-3.49 (m, 4H), 3.92-4.00 (m, 4H), 5.05 (s, 2H), 5.59 (brs, 1H), 6.26-6.40 (m, 3H), 6.50-6.59 (m,
42 3H), 7.10-7.22 (m, 2H), 7.32-7.46 (m, 5H). ESI MS (*m/z*): 491 [M+H]⁺.
43
44
45
46
47
48
49

50 **General Procedure for the synthesis of 3-hydroxyphenoxy derivatives 10 and 11.** A solution of
51 the suitable benzyloxy derivative **8** or **9** (0.63 mmol) in EtOH (5 mL) and EtOAc (5 mL) was
52 hydrogenated (1 atm) at room temperature in the presence of 10% Pd-C (0.05 g) for 16 h. The
53 catalyst was removed by filtration on Celite and the filtrate was concentrated under reduced
54
55
56
57
58
59
60

1
2
3 pressure to afford a crude residue that was purified by silica gel column chromatography (EtOAc as
4
5 eluent) and crystallization.

6
7
8
9 ***N*-{2-((3-(4-(3-Hydroxyphenoxy)butoxy)phenyl)(methylamino)ethyl)acetamide (10).** White
10
11 solid, mp 113-4 °C (EtOAc-petroleum ether), 92% yield. ¹H NMR (CDCl₃) δ: 1.95 (s, 3H), 1.97 (m,
12
13 4H), 2.94 (s, 3H), 3.46-3.50 (m, 4H), 4.02-4.06 (m, 4H), 5.75 (brs, 1H), 6.33-6.49 (m, 6H), 7.00
14
15 (brs, 1H), 7.09-7.18 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ: 171.1, 160.2, 157.5, 151.0, 130.0,
16
17 107.9, 106.7, 105.4, 102.5, 101.8, 99.7, 67.7, 51.8, 38.3, 37.5, 29.7, 26.4, 26.1, 23.1. ESI MS (*m/z*):
18
19 373 [M+H]⁺. HRMS (ESI): *m/z* calculated for C₂₁H₂₉N₂O₄, [M + H]⁺ 373.2127. Found: 373.2154.

20
21
22
23
24 ***N*-{2-((3-(6-(3-Hydroxyphenoxy)hexyloxy)phenyl)(methylamino)ethyl)acetamide (11).** White
25
26 solid, mp 108-9 °C; (EtOAc-petroleum ether), 78% yield. ¹H NMR (CDCl₃) δ: 1.53-1.59 (m, 4H),
27
28 1.78-1.85 (m, 4H), 1.95 (s, 3H), 2.94 (s, 3H), 3.45-3.52 (m, 4H), 3.93-4.01 (m, 4H), 5.80 (brs, 1H),
29
30 6.31-6.48 (m, 6H), 6.72 (brs, 1H), 7.07-7.19 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ: 170.8, 160.4,
31
32 160.3, 157.2, 130.0, 107.8, 106.6, 105.5, 102.5, 102.1, 99.9, 67.7, 67.6, 51.9, 38.1, 37.5, 29.1, 28.9,
33
34 25.8, 23.2. ESI MS (*m/z*): 401 [M+H]⁺. HRMS (ESI): *m/z* calculated for C₂₃H₃₃N₂O₄, [M + H]⁺
35
36 401.2440. Found: 401. 2417.

37
38
39
40
41 **General Procedure for the synthesis of cyclohexyl carbamates 12 and 13.** Cyclohexyl
42
43 isocyanate (62 μl, 0.48 mmol) and Et₃N (5 μL) were added to a solution of the appropriate phenol
44
45 **10** or **11** (0.21 mmol) in absolute EtOH (0.6 mL) and dry CH₃CN (0.6 mL), and the resulting
46
47 mixture was stirred at room temperature for 18 h under a nitrogen atmosphere. After removing the
48
49 solvent by distillation under reduced pressure, the residue was purified by silica gel column
50
51 chromatography (EtOAc-cyclohexane 7:3 as eluent) and crystallization.

3-(4-{3-[(2-Acetamidoethyl)methylamino]phenoxy}butyloxy)phenylcyclohexylcarbamate (12).

White solid, mp 115-6 °C; (EtOAc-petroleum ether), 65% yield. ¹H NMR (CDCl₃) δ: 1.14-1.50 (m, 6H), 1.58-1.80 (m, 4H), 1.93 (s, 3H), 1.92-2.05 (m, 4H), 2.94 (s, 3H), 3.44-3.47 (m, 4H), 3.54-3.58 (m, 1H), 4.00-4.06 (m, 4H), 4.98 (brd, 1H), 5.72 (brs, 1H), 6.30-6.40 (m, 3H), 6.70-6.74 (m, 3H), 7.10-7.23 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ: 170.4, 160.2, 159.8, 153.5, 152.0, 150.9, 130.0, 129.6, 113.7, 111.6, 108.1, 105.5, 102.3, 99.7, 67.6, 67.3, 51.7, 50.1, 38.4, 37.3, 33.2, 26.0, 25.4, 24.7, 23.2. ESI MS (*m/z*): 498 [M+H]⁺. HRMS (ESI): *m/z* calculated for C₂₈H₄₀N₃O₅, [M + H]⁺ 498.2968. Found: 498.2961.

3-(6-{3-[(2-Acetamidoethyl)methylamino]phenoxy}hexyloxy)phenylcyclohexylcarbamate (13).

White solid, mp 99-101 °C; (EtOAc-petroleum ether), 95% yield. ¹H NMR (CDCl₃) δ: 1.17-1.46 (m, 6H), 1.48-1.65 (m, 4H), 1.72-2.04 (m, 8H), 1.94 (s, 3H), 2.94 (s, 3H), 3.45-3.47 (m, 4H), 3.54-3.59 (m, 1H), 3.92-4.01 (m, 4H), 4.95 (brd, 1H), 5.66 (brs, 1H), 6.31-6.40 (m, 3H), 6.69-6.75 (m, 3H), 7.10-7.24 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ: 170.4, 160.4, 159.9, 153.5, 152.0, 150.9, 130.0, 129.5, 113.6, 111.6, 108.1, 105.4, 102.3, 99.8, 67.9, 67.7, 51.8, 50.1, 38.4, 37.3, 33.2, 29.3, 29.1, 25.9, 25.8, 25.4, 24.7, 23.2. ESI MS (*m/z*): 526 [M+H]⁺. HRMS (ESI): *m/z* calculated for C₃₀H₄₄N₃O₅, [M + H]⁺ 526.3281. Found: 526.3251.

***tert*-Butyl (ω-bromoalkyl)carbamates (14a-c).** *tert*-Butyl (8-bromooctyl)carbamate (**14c**) was prepared according to literature procedure and chemical physical data were identical with those previously reported.⁴³ *tert*-Butyl (4-bromobutyl)carbamate (**14a**) and *tert*-butyl (6-bromohexyl)carbamate (**14b**) are commercially available.

General Procedure for the synthesis of *N*-Boc-aminoalkoxyphenyl derivatives 15a-d. The suitable *tert*-butyl (ω-bromoalkyl)carbamate **14a-c** (1.50 mmol), K₂CO₃ (0.315 g, 2.25 mmol) and a catalytic amount of NaI were added to a solution of the appropriate (3-hydroxyanilino)ethylamido

1
2
3 derivative **5a** or **5b** (1.50 mmol) in dry acetone (8 mL), and the resulting mixture was stirred at 60
4 °C for 24 h under a nitrogen atmosphere. After water addition addition the mixture was extracted
5 with EtOAc, the combined organic phases were dried (Na₂SO₄) and the solvent was removed by
6 distillation under reduced pressure to afford a crude residue that was purified by column
7 chromatography.
8
9
10
11
12

13
14
15 **tert-Butyl {4-[3-((2-acetamidoethyl)methylamino)phenoxy]butyl}carbamate (15a)**. This product
16 was obtained following the above general procedure by reacting **5a** with **14a**. Purification by silica
17 gel chromatography (EtOAc as eluent). Oil, 37% yield. ¹H NMR (CDCl₃) δ: 1.45 (s, 9H), 1.65-1.71
18 (m, 2H), 1.77-1.83 (m, 2H), 1.94 (s, 3H), 2.94 (s, 3H), 3.17-3.21 (m, 2H), 3.44-3.48 (m, 4H), 3.98
19 (t, 2H, *J* = 6.5), 4.66 (brs, 1H), 5.71 (brs, 1H), 6.28-6.38 (m, 3H), 7.13 (dd, 1H, *J*₁ = *J*₂ = 8.0). ESI
20 MS (*m/z*): 380 [M+H]⁺.
21
22
23
24
25
26
27
28
29
30

31 **tert-Butyl {4-[3-((2-propionamidoethyl)methylamino)phenoxy]butyl}carbamate (15b)**. This
32 product was obtained following the above general procedure by reacting **5b** with **14b**. Purification
33 by silica gel chromatography (EtOAc-cyclohexane 7:3 as eluent). Oil, 20% yield. ¹H NMR (CDCl₃)
34 δ: 1.12 (t, 3H, *J* = 7.5), 1.45 (s, 9H), 1.38-1.52 (m, 6H), 1.74-1.81 (m, 2H), 2.16 (q, 2H, *J* = 7.5),
35 2.94 (s, 3H), 3.10-3.15 (m, 2H), 3.45-3.49 (m, 4H), 3.94 (t, 2H, *J* = 6.5), 4.55 (brs, 1H), 5.65 (brs,
36 1H), 6.29-6.38 (m, 3H), 7.13 (dd, 1H, *J*₁ = *J*₂ = 8.0). ¹³C NMR (100 MHz, CDCl₃) δ: 174.0, 160.3,
37 156.0, 130.0, 105.5, 102.2, 99.7, 67.6, 51.8, 40.5, 38.4, 37.2, 30.0, 29.6, 29.2, 28.4, 26.5, 25.8, 9.7.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

tert-Butyl {8-[3-((2-acetamidoethyl)methylamino)phenoxy]octyl}carbamate (15c). This product
was obtained following the above general procedure by reacting **5a** with **14c**. Purification by silica
gel chromatography (EtOAc as eluent). Oil, 37% yield. ¹H NMR (CDCl₃) δ: 1.22-1.37 (m, 6H),
1.43 (s, 9H), 1.39-1.48 (m, 4H), 1.70-1.77 (m, 2H), 1.93 (s, 3H), 2.92 (s, 3H), 3.05-3.13 (m, 2H),

1
2
3 3.42-3.46 (m, 4H), 3.93 (t, 2H, $J = 6.5$), 4.52 (brs, 1H), 5.69 (brs, 1H), 6.27-6.37 (m, 3H), 7.12 (dd,
4
5 1H, $J_1 = J_2 = 8.0$). ESI MS (m/z): 436 $[M+H]^+$.
6
7
8

9 ***tert*-Butyl {6-[3-((2-acetamidoethyl)methylamino)phenoxy]hexyl}carbamate (15d)**. This
10 product was obtained following the above general procedure by reacting **5a** with **14b**. Purification
11 by silica gel chromatography (EtOAc as eluent). Oil, 44% yield. ^1H NMR (CDCl_3) δ : 1.36-1.55 (m,
12
13 6H), 1.45 (s, 9H), 1.73-1.82 (m, 2H), 1.95 (s, 3H), 2.94 (s, 3H), 3.08-3.16 (m, 2H), 3.44-3.46 (m,
14
15 4H), 3.95 (t, 2H, $J = 6.5$), 4.55 (brs, 1H), 5.67 (brs, 1H), 6.27-6.40 (m, 3H), 7.14 (dd, 1H, $J_1 = J_2 =$
16
17 8.0). ESI MS (m/z): 408 $[M+H]^+$.
18
19
20
21
22
23

24 **General Procedure for *N*-Boc deprotection: synthesis of aminoalkoxyphenyl derivatives 16a-**
25 **d**. Trifluoroacetic acid (0.8 mL, 10 mmol) was added to an ice-cooled solution of the suitable *N*-
26 Boc derivative **15a-d** (0.3 mmol) in dry CH_2Cl_2 (3.5 mL), and the resulting mixture was stirred at
27 room temperature for 16 h under a nitrogen atmosphere. The reaction mixture was basified by drop-
28 wise addition of a 2N aqueous solution of Na_2CO_3 and extracted with CH_2Cl_2 . The combined
29 organic phases were washed with brine, dried (Na_2SO_4) and the solvent removed by distillation
30 under reduced pressure to give the desired crude amines that were used without further purification
31 or purified by filtration through a pad of silica gel.
32
33
34
35
36
37
38
39
40
41
42
43

44 ***N*-{2-[(3-(4-Aminobutoxy)phenyl)methylamino]ethyl}acetamide (16a)**. Purification by filtration
45 on silica gel (EtOAc-MeOH-conc. NH_3 9:1:1 as eluent). Oil, 60% yield. ^1H NMR (CDCl_3) δ : 1.64-
46 1.71 (m, 2H), 1.77-1.85 (m, 2H), 1.93 (s, 3H), 2.81 (t, 2H, $J = 7.0$), 2.93 (s, 3H), 3.42-3.44 (m, 4H),
47 3.97 (t, 2H, $J = 6.0$), 5.95 (brs, 1H), 6.26-6.31 (m, 2H), 6.35-6.37 (m, 1H), 7.12 (dd, 1H, $J_1 = J_2 =$
48 8.0). ^{13}C NMR (CDCl_3) δ : 170.7, 160.5, 150.4, 130.1, 105.8, 102.5, 99.5, 67.9, 51.7, 42.0, 38.5,
49 37.1, 29.6, 26.7, 23.3. ESI MS (m/z): 280 $[M+H]^+$. HRMS (ESI): m/z calculated for $\text{C}_{15}\text{H}_{26}\text{N}_3\text{O}_2$,
50 $[M + H]^+$ 280.2020. Found: 280.2031.
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 ***N*-{2-[(3-(6-Aminohexyloxy)phenyl)methylamino]ethyl}propionamide (16b)**. This intermediate
6
7 was used for the next step without any further purification. ESI MS (*m/z*): 322 [M+H]⁺.
8
9

10
11 ***N*-{2-[(3-(8-Amino-octyloxy)phenyl)methylamino]ethyl}acetamide (16c)**. This intermediate was
12
13 used for the next step without any further purification. ESI MS (*m/z*): 336 [M+H]⁺.
14
15

16
17 ***N*-{2-[(3-(6-Aminohexyloxy)phenyl)methylamino]ethyl}acetamide (16d)**. Purification by
18
19 filtration on silica gel (EtOAc-MeOH-conc.NH₃ 9:1:1 as eluent). Oil, 64% yield. ¹H NMR (CDCl₃)
20
21 δ: 1.35-1.51 (m, 6H), 1.72-1.79 (m, 2H), 1.91 (s, 3H), 2.69 (t, 2H, *J* = 7.0), 2.91 (s, 3H), 3.41-3.44
22
23 (m, 4H), 3.92 (t, 2H, *J* = 6.5), 5.90 (brs, 1H), 6.23-6.28 (m, 2H), 6.33-6.36 (m, 1H), 7.11 (dd, 1H, *J*₁
24
25 = *J*₂ = 8.0). ¹³C NMR (CDCl₃) δ : 170.6, 160.3, 150.8, 129.9, 105.4, 102.2, 99.5, 67.6, 51.7, 41.7,
26
27 38.4, 37.2, 29.7, 29.2, 26.5, 25.9, 23.1. ESI MS (*m/z*): 308 [M+H]⁺. HRMS (ESI): *m/z* calculated for
28
29 C₁₇H₃₀N₃O₂, [M + H]⁺ 308.2338. Found: 308.2321.
30
31
32
33
34

35 **3'-Hydroxy-(1,1'-biphenyl)-3-carboxamide (18e)**. 3-Bromophenol (0.25 g, 1.44 mmol) and a
36
37 0.4M aqueous solution of Na₂CO₃ (7.5 mL) were added to a solution of 3-carbamoylphenylboronic
38
39 acid (17e) (0.25 g, 1.5 mmol) in CH₃CN (7.5 mL); the reaction mixture was degassed by bubbling
40
41 N₂ for 10 min and then added of Pd(PPh₃)₄ (10 mg). After stirring at 90°C for 1.5 h, the reaction
42
43 mixture was filtered on Celite, the filtrate poured in H₂O and extracted with EtOAc. The combined
44
45 organic phases were dried over Na₂SO₄, filtered and concentrated in vacuo to yield a crude residue
46
47 that was purified by silica gel column chromatography (EtOAc-cyclohexane 8:2 as eluent). White
48
49 solid, 97% yield. Chemical physical data were identical to those previously reported.⁴⁴
50
51
52
53

54 **3'-(Benzyloxy)-[1,1'-biphenyl]-3-ol (18f)**. Na₂CO₃ (0.11 g, 2 mmol), Pd(OAc)₂ (0.001 g) and a
55
56 solution of 3-bromophenol (0.17, 1 mmol) in H₂O (0.7 mL) were added to a solution of 3-
57
58
59
60

(benzyloxy)phenylboronic acid **17f** (0.336 g, 2 mmol) in acetone (3 mL), and the resulting mixture was stirred at 35 °C for 40 min. The mixture was extracted with EtOAc, the combined organic phases were dried (Na₂SO₄) and the solvent removed by distillation under reduced pressure to yield a crude residue that was purified by silica gel column chromatography (cyclohexane-EtOAc 9:1 as eluent). Oil, 81% yield. ¹H NMR (CDCl₃) δ: 5.14 (s, 2H), 5.43 (brs, 1H), 6.84 (ddd, 1H, *J* = 1.0, 2.5 and 8.0), 7.00 (ddd, 1H, *J* = 1.0, 2.5 and 8.0), 7.06-7.07 (m, 1H), 7.16-7.23 (m, 3H), 7.30-7.50 (m, 7H). ESI MS (*m/z*): 275 [M-H]⁻.

General Procedure for the synthesis of carbonates 19d-f. DIPEA (0.15 mL; 0.8 mmol) and a solution of 4-nitrophenyl chloroformate (0.16 g, 0.8 mmol) in dry CH₃CN (4 mL) were added dropwise to a solution of the suitable phenol **18d-f** (0.8 mmol) in dry CH₃CN (2.5 mL), and the resulting mixture was stirred at room temperature for 1 h under a nitrogen atmosphere. Upon completion, the mixture was poured into water and filtered to separate the desired solid precipitate (for **19e**) or extracted with EtOAc (for cpds **19d** and **19f**). The combined organic phases were washed with brine, dried (Na₂SO₄) and the solvent removed by distillation under reduced pressure to give a crude residue that was purified by silica gel column chromatography (cyclohexane-EtOAc 9:1 as eluent) and crystallization.

[1,1'-Biphenyl]-3-yl-(4-nitrophenyl)carbonate (19d). White solid, mp 84-5 °C (EtOAc-petroleum ether); 47% yield. ¹H NMR (CDCl₃) δ: 7.28-7.29 (m, 1H), 7.37-7.67 (m, 8H), 7.51 (d, 2H, *J* = 9.0), 8.34 (d, 2H, *J* = 9.0).

3'-Carbamoyl-[1,1'-biphenyl]-3-yl-(4-nitrophenyl)carbonate (19e). Amorphous solid, 74% yield. ¹H NMR (DMSO-*d*₆) δ: 7.45-7.47 (m, 2H), 7.57-7.64 (m, 2H), 7.73-7.76 (m, 1H), 7.74 (d, 2H, *J* = 9.0), 7.83-7.92 (m, 3H), 8.12 (brs, 1H), 8.21 (brs, 1H), 8.38 (d, 2H, *J* = 9.0). ESI MS (*m/z*): 379 [M+H]⁺.

1
2
3
4
5 **3'-(Benzyloxy)-[1,1'-biphenyl]-3-yl (4-nitrophenyl)carbonate (19f)**. Amorphous solid, 50%
6 yield. ^1H NMR (CDCl_3) δ : 5.14 (s, 2H), 7.01 (dd, 1H, $J = 2.5$ and 8.0), 7.20-7.29 (m, 3H), 7.36-7.53
7 (m, 9H), 7.48 (d, 2H, $J = 9.0$), 8.34 (d, 2H, $J = 9.0$).
8
9
10

11
12
13 **General Procedure for the synthesis of *O*-biphenyl carbamate derivatives 20a-f**. A solution of
14 the appropriate amine **16a-d** (0.23 mmol) in dry CH_2Cl_2 (2 mL, dry DMF for **20e**) and Et_3N (0.14
15 mL, 1.05 mmol) was added to an ice-cooled solution (room temperature for **20e**) of the suitable (4-
16 nitrophenyl)carbonate **19d-f** (0.11 g, 0.33 mmol) in dry CH_2Cl_2 (2 mL) under a nitrogen
17 atmosphere, and the resulting mixture was stirred for 4 h at room temperature. Upon completion of
18 the reaction, a saturated solution of NaHCO_3 was added and the aqueous phase was extracted with
19 CH_2Cl_2 (EtOAc for **20e**). The combined organic phases were washed with brine, dried (Na_2SO_4)
20 and the solvent removed by distillation under reduced pressure to afford a crude residue that was
21 purified by silica gel column chromatography (EtOAc-cyclohexane 8:2 as eluent or EtOAc-MeOH
22 95:5 for **20e**).
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **[1,1'-Biphenyl]-3-yl{4-[3-((2-acetamidoethyl)methylamino)phenoxy]butyl}carbamate (20a)**.

38 This product was obtained starting from amine **16a** and carbonate **19d**. Amorphous solid, 75%
39 yield. ^1H NMR (CDCl_3) δ : 1.64-1.94 (m, 4H), 1.87 (s, 3H), 2.93 (s, 3H), 3.36-3.43 (m, 6H), 4.04 (t,
40 2H, $J = 6.0$), 5.38 (brs, 1H), 5.71 (brs, 1H), 6.29-6.38 (m, 3H), 7.11-7.16 (m, 2H), 7.34-7.44 (m,
41 6H), 7.55-7.57 (m, 2H). ^{13}C NMR (CDCl_3) δ : 170.5, 160.1, 154.7, 151.4, 142.6, 140.3, 130.1,
42 129.5, 128.7, 128.0, 127.6, 127.1, 127.0, 124.0, 120.4, 105.6, 102.2, 99.6, 67.4, 51.7, 40.9, 38.4,
43 37.0, 26.7, 26.4, 23.1. ESI MS (m/z): 476 $[\text{M}+\text{H}]^+$. HRMS (ESI): m/z calculated for $\text{C}_{28}\text{H}_{34}\text{N}_3\text{O}_4$,
44 $[\text{M} + \text{H}]^+$ 476.2549. Found: 476. 2557.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

[1,1'-Biphenyl]-3-yl{6-[3-(methyl(2-propionamidoethyl)amino)phenoxy]hexyl}carbamate

(20b). This product was obtained starting from amine **16b** and carbonate **19d**. Oil, 79% yield. ¹H NMR (CDCl₃) δ: 1.11 (t, 3H, *J* = 7.5), 1.47-1.54 (m, 4H), 1.61-1.66 (m, 2H), 1.79-1.83 (m, 2H), 2.11-2.18 (m, 2H) 2.94 (s, 3H), 3.28-3.34 (m, 2H), 3.44-3.47 (m, 4H), 3.97 (t, 2H, *J* = 6.5), 5.14 (brs, 1H), 5.64 (brs, 1H), 6.28-6.38 (m, 3H), 7.11-7.13 (m, 2H), 7.35-7.45 (m, 6H), 7.54-7.59 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ: 174.1, 160.3, 154.6, 151.4, 150.8, 142.6, 140.3, 130.0, 129.5, 128.7, 127.5, 127.2, 124.0, 120.4, 105.4, 102.1, 99.6, 67.6, 51.7, 41.2, 38.4, 37.2, 29.7, 29.6, 29.2, 26.4, 25.8, 9.7. ESI MS (*m/z*): 518 [M+H]⁺. HRMS (ESI): *m/z* calculated for C₃₁H₄₀N₃O₄, [M + H]⁺ 518.3019. Found: 518.3015.

[1,1'-Biphenyl]-3-yl{8-[3-((2-acetamidoethyl)methylamino)phenoxy]octyl}carbamate (20c).

This product was obtained starting from amine **16c** and carbonate **19d**. Amorphous solid, 90% yield. ¹H NMR (CDCl₃) δ: 1.34-1.47 (m, 6H), 1.48-1.52 (m, 2H), 1.58-1.64 (m, 2H), 1.71-1.82 (m, 2H), 1.93 (s, 3H), 2.94 (s, 3H), 3.25-3.31 (m, 2H), 3.44-3.46 (m, 4H), 3.95 (t, 2H, *J* = 6.5), 5.10 (brs, 1H), 5.63 (brs, 1H), 6.27-6.41 (m, 3H), 7.09-7.17 (m, 2H), 7.32-7.47 (m, 6H), 7.55-7.61 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ: 170.4, 160.4, 154.6, 151.4, 150.9, 142.6, 140.3, 130.0, 129.5, 128.7, 127.5, 127.2, 124.0, 120.4, 105.5, 102.3, 99.7, 67.7, 51.8, 41.3, 38.4, 37.4, 29.8, 29.3, 29.2, 29.1, 26.6, 26.0, 23.2. ESI MS (*m/z*): 532 [M+H]⁺. HRMS (ESI): *m/z* calculated for C₃₂H₄₂N₃O₄, [M + H]⁺ 532.3175. Found: 532.3183.

[1,1'-Biphenyl]-3-yl{6-[3-((2-acetamidoethyl)methylamino)phenoxy]hexyl}carbamate (20d).

This product was obtained starting from amine **16d** and carbonate **19d**. Oil, 85% yield. ¹H NMR (CDCl₃) δ: 1.58-1.65 (m, 6H), 1.71-1.89 (m, 2H), 1.93 (s, 3H), 2.95 (s, 3H), 3.26-3.37 (m, 2H), 3.44-3.46 (m, 4H), 3.98 (t, 2H, *J* = 6.0), 5.18 (brs, 1H), 5.70 (brs, 1H), 6.26-6.49 (m, 3H), 7.11-7.18 (m, 2H), 7.28-7.47 (m, 6H), 7.56-7.61 (m, 2H). ¹³C NMR (CDCl₃) δ: 170.5, 160.1, 154.7, 151.4, 142.6, 140.3, 130.1, 129.5, 128.7, 128.0, 127.6, 127.1, 127.0, 124.0, 120.4, 105.6, 102.2, 99.6, 67.5,

1
2
3 51.7, 41.2, 38.5, 37.1, 29.7, 29.3, 26.4, 25.7, 23.1. ESI MS (m/z): 504 $[M+H]^+$. HRMS (ESI): m/z
4
5 calculated for $C_{30}H_{38}N_3O_4$, $[M + H]^+$ 504.2862. Found: 504.2856
6
7
8

9
10 **3'-Carbamoyl-[1,1'-biphenyl]-3-yl{6-[3-((2-**

11 **acetamidoethyl)methylamino)phenoxy]hexyl}carbamate (20e).** This product was obtained
12 starting from amine **16a** and carbonate **19e**. Purification by silica gel chromatography (EtOAc-
13 MeOH 95:5 as eluent). Amorphous solid, 38% yield. 1H NMR ($CDCl_3$) δ : 1.47-1.54 (m, 4H), 1.60-
14 1.67 (m, 2H), 1.77-1.84 (m, 2H), 1.88 (s, 3H), 2.91 (s, 3H), 3.29-3.38 (m, 2H), 3.49-3.41 (m, 4H),
15 3.97 (t, 2H, $J = 6.5$), 5.27 (brs, 1H), 5.73 (brs, 1H), 5.84 (brs, 1H), 6.28-6.35 (m, 3H), 6.46 (brs,
16 1H), 7.11-7.15 (m, 2H), 7.36-7.54 (m, 4H), 7.37 (d, 1H, $J = 8.0$), 7.81 (d, 1H, $J = 8.0$), 7.99-8.01
17 (m, 1H). ^{13}C NMR ($CDCl_3$) δ : 170.6, 169.3, 160.3, 154.7, 153.9, 151.5, 141.6, 140.8, 134.0, 130.6,
18 130.0, 129.7, 129.1, 126.5, 126.2, 124.1, 121.0, 120.6, 105.5, 102.2, 99.6, 67.6, 51.7, 41.1, 38.4,
19 37.2, 29.6, 29.1, 26.3, 25.7, 23.2. ESI MS (m/z): 547 $[M+H]^+$. HRMS (ESI): m/z calculated for
20 $C_{31}H_{39}N_4O_5$, $[M + H]^+$ 547.2920. Found: 547.2940.
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 **3'-(Benzyloxy)-[1,1'-biphenyl]-3-yl** **{6-[3-((2-**

36 **acetamidoethyl)methylamino)phenoxy]hexyl}carbamate (20f).** This product was obtained
37 starting from amine **16a** and carbonate **19f**. Oil, 57% yield. 1H NMR ($CDCl_3$) δ : 1.47-1.66 (m, 6H),
38 1.77-1.83 (m, 2H), 1.92 (s, 3H), 2.93 (s, 3H), 3.29-3.34 (m, 2H), 3.43-3.45 (m, 4H), 3.97 (t, 2H, $J =$
39 6.5), 5.12 (s, 2H), 5.13 (brs, 1H), 5.66 (brs, 1H), 6.29-6.41 (m, 3H), 6.97 (dd, 1H, $J = 2.0$ and 8.0),
40 7.10-7.22 (m, 4H), 7.32-7.48 (m, 9H). ESI MS (m/z): 610 $[M+H]^+$.
41
42
43
44
45
46
47
48
49

50 **3'-Hydroxy-[1,1'-biphenyl]-3-yl** **{6-[3-((2-**

51 **acetamidoethyl)methylamino)phenoxy]hexyl}carbamate (20g).** A solution of the benzyloxy
52 derivative **20f** (0.13 g, 0.21 mmol) in EtOH (0.5 mL) and EtOAc (2.5 mL) was hydrogenated (1
53 atm) at room temperature in the presence of 10% Pd-C (0.03 g) for 20 h. The catalyst was removed
54
55
56
57
58
59
60

1
2
3 by filtration on Celite and the filtrate concentrated under reduced pressure to afford a crude product
4
5 which was purified by silica gel chromatography (EtOAc as eluent). Amorphous solid, 76% yield.
6
7 ^1H NMR (CDCl_3) δ : 1.44-1.57 (m, 4H), 1.58-1.66 (m, 2H), 1.76-1.83 (m, 2H), 1.93 (s, 3H), 2.91 (s,
8
9 3H), 3.28-3.33 (m, 2H), 3.42-3.44 (m, 4H), 3.98 (t, 2H, $J = 6.5$), 5.18 (brs, 1H), 5.81 (brs, 1H),
10
11 6.32-6.37 (m, 3H), 6.84 (dd, 1H, $J = 2.0$ and 8.0), 7.02-7.04 (m, 1H), 7.07-7.18 (m, 3H), 7.25-7.29
12
13 (m, 2H), 7.30-7.32 (m, 1H), 7.38-7.40 (m, 2H). ^{13}C NMR (CDCl_3) δ : 170.1, 160.3, 156.7, 154.9,
14
15 151.3, 142.5, 141.7, 130.1, 129.9, 129.5, 124.0, 120.4, 120.3, 119.0, 114.8, 114.2, 105.6, 102.7,
16
17 99.9, 67.8, 51.9, 41.1, 38.5, 37.2, 29.6, 29.0, 26.3, 25.7, 23.1. ESI MS (m/z): 520 $[\text{M}+\text{H}]^+$. HRMS
18
19 (ESI): m/z calculated for $\text{C}_{30}\text{H}_{38}\text{N}_3\text{O}_5$, $[\text{M} + \text{H}]^+$ 520.2811. Found: 520.2798.
20
21
22
23

24 **General Procedure for the Synthesis of 5-(*N*-Boc-aminoalkoxy)-*N*-acetyltryptamines 21-22.**

25 K_2CO_3 (0.19 g, 1.4 mmol) was added to a solution of *N*-acetylserotonin (0.10 g, 0.46 mmol) in dry
26
27 CH_3CN (3 mL) and the resulting mixture was stirred under reflux for 1 h under a nitrogen
28
29 atmosphere. Then a solution of the suitable *N*-Boc-derivative **14b** or **14c** (0.46 mmol) in dry
30
31 CH_3CN (2 mL) and a catalytic amount of NaI were added and the resulting mixture was refluxed
32
33 for 20 h. Water was added to quench the reaction and the aqueous phase was extracted with EtOAc.
34
35 The combined organic phases were dried (Na_2SO_4) and concentrated under reduced pressure to give
36
37 a crude residue that was purified by silica gel column chromatography (EtOAc as eluent).
38
39
40
41
42
43

44 ***tert*-Butyl (6-{{3-(2-acetamidoethyl)-1*H*-indol-5-yl}oxy}hexyl)carbamate (21).** Amorphous solid;
45
46 59% yield. ^1H NMR (CDCl_3) δ : 1.38-1.56 (m, 4H), 1.48 (s, 9H), 1.78-1.85 (m, 4H), 1.96 (s, 3H),
47
48 2.95 (t, 2H, $J = 6.5$), 3.13-3.15 (m, 2H), 3.59-3.61 (m, 2H), 4.00 (t, 2H, $J = 6.5$), 4.55 (brs, 1H),
49
50 5.75 (brs, 1H), 6.87 (dd, 1H, $J = 2.0$ and 8.5), 7.03-7.05 (m, 2H), 7.26 (d, 1H, $J = 8.5$), 7.97 (brs,
51
52 1H). ESI MS (m/z): 418 $[\text{M}+\text{H}]^+$. ESI MS (m/z): 416 $[\text{M}-\text{H}]^-$.
53
54
55
56
57
58
59
60

1
2
3 **tert-Butyl (8-{[3-(2-acetamidoethyl)-1H-indol-5-yl]oxy}octyl)carbamate (22).** White solid, mp
4 75-6 °C; (EtOAc-petroleum ether), 47% yield. ¹H NMR (CDCl₃) δ: 1.29–1.41 (m, 6H), 1.42–1.54
5 (m, 4H), 1.45 (s, 9H), 1.78-1.82 (m, 2H), 1.95 (s, 3H), 2.95 (t, 2H, *J* = 6.5), 3.08-3.11 (m, 2H),
6 3.58-3.61 (m, 2H), 4.00 (t, 2H, *J* = 6.5), 4.52 (brs, 1H), 5.75 (brs, 1H), 6.88 (dd, 1H, *J* = 2.0 and
7 8.5), 7.02-7.04 (m, 2H), 7.27 (d, 1H, *J* = 8.5), 8.01 (brs, 1H). ESI MS (*m/z*): 446 [M+H]⁺ · ESI MS
8 (*m/z*): 444 [M-H]⁻.

9
10
11
12
13
14
15
16
17
18 **tert-Butyl (6-{[3-(2-acetamidoethyl)-2-bromo-1H-indol-5-yl]oxy}hexyl)carbamate (23).**
19
20 Trimethyl phenyl ammonium tribromide (0.050 g, 0.132 mmol) was added to a solution of **21**
21 (0.055 g, 0.132 mmol) in dry THF (2.5 mL) and the resulting mixture was stirred at room
22 temperature for 30 min under a nitrogen atmosphere. After removing the solvent by distillation
23 under reduced pressure, the residue was partitioned between water and EtOAc. The combined
24 organic phases were dried (Na₂SO₄) and concentrated under reduced pressure to afford a crude
25 residue that was purified by silica gel column chromatography (EtOAc-cyclohexane 6:4 as eluent).
26 Oil, 59% yield. ¹H NMR (CDCl₃) δ: 1.34-1.52 (m, 6H), 1.45 (s, 9H), 1.76-1.80 (m, 2H), 1.94 (s,
27 3H), 2.90 (t, 2H, *J* = 6.5), 3.11-3.15 (m, 2H), 3.51-3.54 (m, 2H), 3.96 (t, 2H, *J* = 6.5), 4.63 (brs,
28 1H), 5.72 (brs, 1H), 6.81 (dd, 1H, *J* = 2.0 and 8.5), 6.94-6.96 (m, 1H), 7.19 (d, 1H, *J* = 8.5), 8.71
29 (brs, 1H). ESI MS (*m/z*): 496 [M+H]⁺.

30
31
32
33
34
35
36
37
38
39
40
41
42
43
44 **General Procedure for the synthesis of indole target compounds 27-29.** (CH₃)₃SiBr (48 μl, 0.36
45 mmol) was added to a solution of the suitable *N*-Boc-derivative **21-23** (0.12 mmol) in dry CH₃CN
46 (1.2 mL) and the resulting mixture was stirred at room temperature for 1 h under a nitrogen
47 atmosphere. Upon completion of the reaction, MeOH was added and the resulting mixture was
48 concentrated in vacuo to give the corresponding crude amine that was used for the next step without
49 any further purification.
50
51
52
53
54
55
56
57
58
59
60

Et₃N (0.075 mL, 0.53 mmol) and a solution of the suitable above crude amine (**24-26**) in dry CH₂Cl₂ (2 mL) and DMF (0.2 mL) were added to an ice-cooled solution of carbonate **19d** (0.06 g, 0.17 mmol) in dry CH₂Cl₂ (1 mL) under a nitrogen atmosphere, and the resulting mixture was stirred at room temperature for 3 h. The reaction mixture was neutralized by addition of an aqueous saturated solution of NaHCO₃ and extracted with CH₂Cl₂. The combined organic phases were dried (Na₂SO₄) and concentrated under reduced pressure to afford a crude residue that was purified by column chromatography.

[1,1'-Biphenyl]-3-yl(6-((3-(2-aminoethyl)-1H-indol-5-yl)oxy)hexyl)carbamate (27). Purification by silica gel chromatography (EtOAc as eluent) and crystallization. White solid, mp 100-1 °C (EtOAc-petroleum ether); 83% yield. ¹H NMR (CDCl₃) δ: 1.43-1.70 (m, 6H), 1.81-1.88 (m, 2H), 1.93 (s, 3H), 2.93 (t, 2H, *J* = 6.5), 3.31-3.34 (m, 2H), 3.57-3.60 (m, 2H), 4.03 (t, 2H, *J* = 6.5), 5.20 (brs, 1H), 5.70 (brs, 1H), 6.89 (dd, 1H, *J* = 2.0 and 8.5), 6.99-7.02 (m, 1H), 7.05 (d, 1H, *J* = 2.0), 7.10-7.13 (m, 1H), 7.24-7.26 (m, 1H), 7.33-7.37 (m, 2H), 7.41-7.45 (m, 4H), 7.55-7.59 (m, 2H), 8.02 (brs, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 170.8, 154.6, 153.5, 151.4, 142.6, 140.3, 131.5, 129.5, 128.7, 127.8, 127.5, 127.2, 127.1, 124.0, 122.7, 120.4, 113.0, 112.7, 111.9, 101.8, 68.7, 41.2, 39.8, 29.8, 29.3, 26.5, 25.8, 25.3, 23.3. ESI MS (*m/z*): 514 [M+H]⁺. HRMS (ESI): *m/z* calculated for C₃₁H₃₆N₃O₄, [M + H]⁺ 514.2706. Found: 514.2700.

[1,1'-Biphenyl]-3-yl(8-((3-(2-aminoethyl)-1H-indol-5-yl)oxy)octyl)carbamate (28). Purification by silica gel chromatography (EtOAc as eluent) and crystallization. White solid, mp 108-9 °C (EtOAc-petroleum ether); 95% yield. ¹H NMR (CDCl₃) δ: 1.26-1.67 (m, 10H), 1.80-1.85 (m, 2H), 1.93 (s, 3H), 2.94 (t, 2H, *J* = 6.5), 3.27-3.32 (m, 2H), 3.57-3.62 (m, 2H), 4.01 (t, 2H, *J* = 6.5), 5.10 (brs, 1H), 5.68 (brs, 1H), 6.88 (dd, 1H, *J* = 2.0 and 8.5), 7.01-7.03 (m, 1H), 7.04-7.05 (d, 1H, *J* = 2.0), 7.10-7.14 (m, 1H), 7.25-7.29 (m, 1H), 7.35-7.38 (m, 2H), 7.41-7.46 (m, 4H), 7.57-7.60 (m, 2H), 7.96 (brs, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 170.8, 154.6, 153.5, 151.4, 142.6, 140.3,

1
2
3 131.5, 129.5, 128.7, 127.8, 127.5, 127.2, 124.0, 122.7, 120.4, 113.0, 112.7, 111.9, 101.7, 68.8, 41.3,
4
5 39.8, 29.8, 29.4, 29.2, 29.1, 26.6, 26.0, 25.2, 23.3. ESI MS (m/z): 542 $[M+H]^+$. HRMS (ESI): m/z
6
7 calculated for $C_{33}H_{40}N_3O_4$, $[M + H]^+$ 542.3019. Found: 542.3044.
8
9

10
11 **[1,1'-Biphenil]-3-yl(6-((3-(2-aminoethyl)-2-bromo-1*H*-indol-5-yl)oxy)hexyl)-carbamate (29).**

12 Purification by silica gel chromatography (cyclohexane-EtOAc 7:3 as eluent). Amorphous solid;
13
14 83% yield. 1H NMR ($CDCl_3$) δ : 1.44-1.57 (m, 4H), 1.62-1.67 (m, 2H), 1.80-1.84 (m, 2H), 1.94 (s,
15
16 3H), 2.89 (t, 2H, $J = 6.5$), 3.30-3.31 (m, 2H), 3.48-3.52 (m, 2H), 4.01 (t, 2H, $J = 6.5$), 5.27 (brs,
17
18 1H), 6.18 (brs, 1H), 6.83 (dd, 1H, $J = 2.0$ and 8.5), 6.97-6.99 (m, 1H), 7.11-7.15 (m, 1H), 7.13 (d,
19
20 1H, $J = 8.5$), 7.37-7.39 (m, 2H), 7.40-7.43 (m, 4H), 7.54-7.57 (m, 2H), 8.18 (brs, 1H). ^{13}C NMR
21
22 ($CDCl_3$) δ : 171.0, 154.8, 153.8, 151.4, 142.6, 140.3, 131.3, 129.6, 128.7, 128.1, 127.6, 127.2,
23
24 124.0, 120.4, 120.4, 112.8, 111.9, 111.5, 108.9, 101.2, 68.7, 41.2, 39.6, 29.7, 29.2, 26.5, 25.8, 24.7,
25
26 22.9. ESI MS (m/z): 592 $[M+H]^+$. HRMS (ESI): m/z calculated for $C_{31}H_{35}N_3O_4Br$, $[M + H]^+$
27
28 592.1811. Found: 592.1844.
29
30
31
32
33
34

35 **Molecular modelling**

36
37 **Protein preparation.** The X-ray structure of rFAAH in its covalent adduct with methylarachidonyl
38
39 phosphonate (MAP; PDB: 1MT5⁴⁵) was used for docking studies. The complete structure of chain
40
41 A and a portion of chain B, including the α -helix involved in the dimerization surface (Pro438-
42
43 Asn466), were prepared using the Protein Preparation Wizard tool⁴⁶ of the Schrodinger 2015-4
44
45 software suite and modeled using the OPLS2005 force field.^{47,48} The bound inhibitor was removed
46
47 and missing hydrogen atoms were added. Basic and acid amino acids were modeled in their charged
48
49 form, except for K142, which is part of the catalytic site and was maintained neutral. The
50
51 orientation of thiol and hydroxyl groups, the conformations of asparagine, glutamine and histidine
52
53 residues were adjusted to optimize the overall hydrogen bonding network. The model was first
54
55 submitted to a minimization in which the heavy atoms were restrained, leaving the hydrogen atoms
56
57
58
59
60

1
2
3 free to move. A second minimization was performed, restraining the position of the heavy atoms to
4
5 an RMSD value of 0.3 Å.

6
7 A previously reported homology model of the MT₁ receptor³⁰ was used for induced-fit docking
8
9 studies.

10
11 ***rFAAH docking studies.*** Ligands were built using Maestro 10.4⁴⁹ and optimized using LigPrep.⁵⁰
12
13 Docking was performed with Glide 6.9.^{51,52} The docking grid was centered on the position of the
14
15 covalent inhibitor, with enclosing and bounding box dimensions set to 24 Å and 33 Å, respectively.
16
17 Hydrogen bond constraints were imposed between the carbamate oxygen of the ligands and the
18
19 backbone nitrogen atoms of Ile238 and Gly239, and between the carbamate nitrogen of the ligands
20
21 and the backbone oxygen atom of Met191. Ligand docking was performed in standard precision
22
23 mode with default settings. The resulting binding poses were ranked according to their Emodel
24
25 score. The best-ranked poses were merged into the protein structure and the complexes were
26
27 minimized with the OPLS2005 force field implemented in MacroModel 11.0,⁵³ applying the Polak-
28
29 Ribiere conjugate gradient method to a convergence threshold of 0.05 kJ mol⁻¹ Å⁻¹. During energy
30
31 minimization the ligands and residues within 10 Å from them were free to move, while the
32
33 backbone of the other residues was kept fixed.
34
35

36
37 ***MT₁ induced-fit docking studies.*** The docking grid was centered on the putative binding site of the
38
39 MT₁ receptor, comprising Tyr187^{5,38}, Trp251^{6,48} and Tyr285^{7,43}, setting the dimension of the
40
41 enclosing and bounding boxes to 15 Å and 30 Å, respectively. As a first step, a softened-potential
42
43 docking run was performed applying van der Waals radii scaling factors of 0.7 and 0.5 on protein
44
45 and ligand non-polar atoms, respectively. Residues Asn169 and Tyr175, which are situated on
46
47 extracellular loop 2, were temporarily mutated to alanine. To reproduce the polar contacts that have
48
49 been postulated for melatonergic agonists, hydrogen bonds constraints were imposed between the
50
51 hydroxyl group of Tyr187 and the phenolic oxygen of the ligands, and between the hydroxyl group
52
53 of Tyr285 and the amide C=O group of the ligands. The resulting complexes were then submitted to
54
55 a protein refinement procedure. In this stage, once the amino acid side chains previously mutated to
56
57
58
59
60

alanine (i.e., Asn169 and Tyr175) were rebuilt, all residues within a shell of 5 Å from the ligand poses, except for Tyr187 and Tyr285, were refined through a conformational search using Prime.⁵⁴ During the last step of the induced-fit docking protocol, the ligand structures were optimized in the field of the refined receptor binding site, and finally scored using the default Glide settings. The ligand-protein complexes obtained were ranked according to their induced-fit docking score, which is a composite score accounting for ligand-receptor interaction energy, receptor strain and solvation terms. The best-ranked complexes were finally minimized with the OPLS2005 force field implemented in MacroModel, applying the Polak-Ribiere conjugate gradient method to a convergence threshold of 0.05 kJ mol⁻¹ Å⁻¹. During the minimization ligands and residues within 10 Å from them were free to move, while the backbone of other residues was kept fixed.

Pharmacology

Melatonin receptor binding and intrinsic activity evaluation. Binding affinities were determined using 2-[¹²⁵I]iodomelatonin as the labeled ligand in competition experiments on cloned human MT₁ and MT₂ receptors expressed in NIH3T3 rat fibroblast cells. The characterization of NIH3T3-MT₁ and -MT₂ cells had been already described in detail.^{55,56} Membranes were incubated for 90 min at 37 °C in binding buffer (Tris-HCl, 50 mM, pH 7.4). The final membrane concentration was 5–10 μg of protein per tube. The membrane protein level was determined in accordance with a previously reported method.⁵⁷ 2-[¹²⁵I]Iodomelatonin (100 pM) and different concentrations of MLT (10⁻¹⁰–10⁻⁶ M) or of the new compounds were incubated with the receptor preparation for 90 min at 37 °C. Nonspecific binding was assessed with 10 μM MLT; IC₅₀ values were determined by nonlinear fitting strategies with the program PRISM (GraphPad SoftWare Inc., San Diego, CA). The pK_i values were calculated from the IC₅₀ values in accordance with the Cheng–Prusoff equation.³⁶ The pK_i values are the mean of at least three independent determinations performed in duplicate.

To define the functional activity of the new compounds at MT₁ and MT₂ receptor subtypes, [³⁵S]GTPγS binding assays in NIH3T3 cells expressing human-cloned MT₁ or MT₂ receptors were

1
2
3 performed. The amount of bound [^{35}S]GTP γ S is proportional to the level of the analogue-induced
4 G-protein activation and is related to the intrinsic activity of the compound under study. The
5 detailed description and validation of this method were reported elsewhere.^{56,58} Membranes (15–25
6 μg of protein, final incubation volume 100 μL) were incubated at 30 °C for 30 min in the presence
7 and in the absence of MLT analogues in an assay buffer consisting of [^{35}S]GTP γ S (0.3–0.5 nM),
8 GDP (50 μM), NaCl (100 mM), and MgCl₂ (3 mM). Nonspecific binding was defined using
9 [^{35}S]GTP γ S (10 μM). In cell lines expressing human MT₁ or MT₂ receptors, MLT produced a
10 concentration dependent stimulation of basal [^{35}S]GTP γ S binding with a maximal stimulation,
11 above basal levels, of 370% and 250% in MT₁ and MT₂ receptors, respectively. Basal stimulation is
12 the amount of [^{35}S]GTP γ S specifically bound in the absence of compounds, and it was taken as
13 100%. The maximal G-protein activation was measured in each experiment by using MLT (100
14 nM). Compounds were added at three different concentrations (one concentration was equivalent to
15 100 nM MLT, a second one 10 times smaller, and a third one 10 times larger), and the percent
16 stimulation above basal was determined. The equivalent concentration was estimated on the basis of
17 the ratio of the affinity of the test compound to that of MLT. It was assumed that at the equivalent
18 concentration the test compound occupies the same number of receptors as 100 nM MLT. All of the
19 measurements were performed in triplicate. The relative intrinsic activity (I_{Ar}) values were
20 obtained by dividing the maximum ligand-induced stimulation of [^{35}S]GTP γ S binding by that of
21 MLT as measured in the same experiment. By convention, the natural ligand MLT has an efficacy
22 (E_{max}) of 100%. Full agonists stimulate [^{35}S]GTP γ S binding with a maximum efficacy, close to that
23 of MLT itself. If E_{max} is between 30% and 70% that of MLT ($0.3 < \text{IAr} < 0.7$), the compound is
24 considered a partial agonist, whereas if E_{max} is lower than 30% ($\text{IAr} < 0.3$), the compound is
25 considered an antagonist.⁵⁹

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55 **FAAH activity assay.** Wistar rat was anesthetized with isoflurane and decapitated. The brain was
56 removed and homogenized in ice-cold Tris buffer (10 volumes, 50 mM, pH 7.5) containing sucrose
57
58
59
60

1
2
3 (0.32 M). The homogenates were centrifuged at $1,000 \times g$ for 10 min at 4 °C, and FAAH activity
4 was measured using the supernatant (homogenate). Protein concentrations were determined with the
5 BCA protein assay kit (Thermo Scientific, Rockford, USA). FAAH activity was measured by using
6
7 [^3H]anandamide (anandamide[ethanolamine- ^3H], 60 Ci mmol^{-1} , American Radiolabeled Chemicals,
8 St. Louis, USA) as substrate. Homogenates (50 μg protein) were incubated for 30 min at 37 °C in
9
10 Tris buffer (50 mM, pH 7.5, 0.5 mL) containing fatty-acid-free bovine serum albumin (BSA, 0.05
11
12 %, w/v), 10 μM anandamide and [^3H]anandamide (20,000 cpm), and varying concentrations of test
13
14 compounds. The reactions were stopped with 1 mL $\text{CHCl}_3/\text{MeOH}$ (1:1) and centrifugation at 2,000
15
16 $\times g$ for 10 min at 4 °C. Radioactivity in the aqueous layer ([^3H]ethanolamine) was measured by
17
18 liquid scintillation counting. For in vitro experiments, the drugs were dissolved in DMSO and final
19
20 DMSO concentration was 1 %.

21
22
23
24
25
26 ***Rabbit IOP lowering studies.*** The experimental procedures were carried out in New Zealand albino
27 rabbits. We followed the Resolution of the Association for Research in Vision and Ophthalmology,
28 the Good Laboratory Practice for the use of animals upon the authorization of Italian regulation on
29 protection of animals (DM 116/1992) and from the Italian Health Ministry (Authorization N°
30 1179/2015-PR), in agreement with the European Union Regulations (OJ of ECL 358/1,
31 12/12/1986). Male albino rabbits (New Zealand White NZW rabbits from Envigo RMS S.r.l., S.
32 Pietro al Natisone, Udine, Italy) aged 2-3 months (body weight 2-2.5 kg) were kept in individual
33 cages, food and water was provided ad libitum. The animals were maintained on a 12-12 h
34 light/dark cycle in a temperature controlled room (22-23 °C). Male albino SPF (specific pathogen
35 free) New Zealand rabbits were used for the procedures. Animals were identified with a tattoo in
36 the ear, numbered consecutively and examined before the beginning of the study to verify the good
37 general and ophthalmic health condition. Tested compounds were dissolved in pyrogen free sterile
38 0.9% NaCl solution (i.e., physiologic solution) and 0.1% DMSO, 0.1% EtOH at 1 mM
39 concentration. Vehicle was 0.9% NaCl + 0.1% DMSO and 0.1% EtOH. The reference compound
40 dorzolamide (**30**) was used at 1% concentration (w/v). The Draize Eye Test was used to establish if
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the formulation of each test compound was suitable for dosing the animals used in the in vivo rabbit
4 model by showing no acute toxicity (see Supporting Information for test details).⁶⁰ Compounds
5 were instilled into the lower conjunctival pocket. All the compounds were given prior to saline
6 injection and the IOP was measured at the very beginning of the experimental session to establish
7 basal IOP. Four different animals were used for each tested compounds. One eye was treated with
8 0.05 mL of drug solution and the contralateral eye received the same volume of vehicle. Co-
9 administration of compounds **1** and **2** was obtained with 0.05 mL of solution containing both
10 compounds at 1 mM concentration. Ocular hypertension was induced by the injection of 0.05 mL of
11 sterile hypertonic saline (5%) into the vitreous bilaterally with local anaesthesia provided by one
12 drop of 0.2 % oxybuprocaine hydrochloride in each eye one minute before. IOP was measured
13 using a Model 30™ Pneumatometer (Reichert Inc. Depew, NY, USA) after hypertonic saline
14 injection after stabilization (normally 10 minutes) to verify the rise of IOP into the suitable
15 experimental range (IOP > 30 and < 40 mm Hg) and after 60, 120, 240 minutes in all groups after
16 drug or vehicle treatment. One drop of 0.2% oxybuprocaine hydrochloride was instilled in each eye
17 immediately before each set of pressure measurements.

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35 Data were analyzed with 2-way Anova followed by Bonferroni multiple comparison test. P value
36 p<0.05 was used to identify significance.
37
38
39
40

41 **Supporting information**

42 The Supporting Information is available free of charge on the ACS Publications website.

43
44
45
46 Molecular formula strings data (CSV)

47
48 Purity of target compounds, details on ocular irritation and safety assessment test, intraocular
49 pressure (IOP) values measured for compounds **1**, **2**, **20c**, **20e**, **20g**, **27**, **28**, **29**, **30**, and for co-
50 administration of **1** and **2** (PDF).
51
52
53

54 55 56 57 **Author Information**

1
2
3 Corresponding Author Silvia Rivara

4 *Phone: +39 0521 906061 Fax: + 39 0521 905006 E-mail: silvia.rivara@unipr.it

6
7
8
9 **Acknowledgements**

10 This work was carried out using the HPC (High Performance Computing) computational facilities
11 of the University of Parma, Italy - <http://www.hpc.unipr.it>.

12
13
14
15
16
17
18 **Notes**

19 The authors declare no competing financial interest.

20
21
22
23
24 **Abbreviations**

25 DIPEA, *N,N*-diisopropylethylamine; DMF, dimethylformamide; FAAH, fatty acid amide hydrolase;
26 GTP γ S, guanosine 5'-O-(3-thiotriphosphate); Emax, maximum activation of receptor; HPLC, high-
27 performance liquid chromatography; IOP, intraocular pressure; MLT, melatonin; MT₁, melatonin
28 receptor subtype 1; MT₂, melatonin receptor subtype 2; TFA, trifluoroacetic acid; THF,
29 tetrahydrofuran.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- ¹ Jonas, J. B.; Aung, T.; Bourne, R. R.; Bron, A. M.; Ritch, R.; Panda-Jonas, S. Glaucoma. *Lancet* **2017**, *390*, 2183–2193.
- ² Dikopf, M. S.; Vajaranant, T. S.; Edward, D. P. Topical treatment of glaucoma: established and emerging pharmacology. *Expert Opin. Pharmacother.* **2017**, *18*, 885–898.
- ³ Olthoff, C. M.; Schouten, J. S.; van de Borne, B. W.; Webers, C. A. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. *Ophthalmology.* **2005**, *112*, 953–961.
- ⁴ Hollo, G.; Topouzis, F.; Fechtner, R. D. Fixed combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. *Expert Opin. Pharmacother.* **2014**, *15*, 1737–1747.
- ⁵ Higginbotham E. J. Considerations in glaucoma therapy: fixed combinations versus their component medications. *Clin. Ophthalmol.* **2010**, *4*, 1–9.
- ⁶ Babic N. Fixed combinations of glaucoma medications. *Srp. Arh. Celok. Lek.* **2015**, *143*, 626–631.
- ⁷ Konstas, A. G. P.; Quaranta, L.; Katsanos, A.; Voudouragkaki, I. C.; Dutton, G. N. Fixed combination therapies in glaucoma. In *Glaucoma*, 2nd ed.; Shaarawy T. M., Sherwood M. B., Hitchings R. A., Crowston J. G. Eds.; Elsevier Saunders, 2015; pp 583-592.
- ⁸ Samples, J. R.; Krause, G.; Lewy, A. J. Effect of melatonin on intraocular pressure. *Curr. Eye Res.* **1988**, *7*, 649–653.
- ⁹ Crooke, A.; Colligris, B.; Pintor, J. Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues. *Curr. Med. Chem.* **2012**, *19*, 3508–3522.
- ¹⁰ Jockers, R.; Delagrang, P.; Dubocovich, M.L.; Markus R. P.; Renault N.; Tosini, G.; Cecon E.; Zlotos, D. P. Update on melatonin receptors: IUPHAR review 20. *Br. J. Pharmacol.* **2016**, *173*, 2702–2725.

-
- 1
2
3
4
5 ¹¹ Zlotos, D. P.; Jockers, R.; Cecon, E.; Rivara, S.; Witt-Enderby, P. A. MT₁ and MT₂ melatonin
6 receptors: ligands, models, oligomers, and therapeutic potential. *J. Med. Chem.* **2014**, *57*,
7 3161–3185.
8
9
10
11 ¹² Hardeland, R.; Cardinali, D. P.; Srinivasan, V.; Spence, D. W.; Brown, G.M.; Pandi-Perumal,
12 S.R. Melatonin--a pleiotropic, orchestrating regulator molecule. *Prog. Neurobiol.* **2011**, *93*,
13 350–384.
14
15
16
17 ¹³ Alarma-Estrany, P.; Pintor, J. Melatonin receptors in the eye: location, second messengers and
18 role in ocular physiology. *Pharmacol. Ther.* **2007**, *113*, 507–522.
19
20
21
22 ¹⁴ Martínez-Águila, A.; Fonseca, B.; Pérez de Lara, M. J.; Pintor, J. Effect of melatonin and 5-
23 methoxycarbonylamino-N-acetyltryptamine on the intraocular pressure of normal and glaucomatous
24 mice. *J. Pharmacol. Exp. Ther.* **2016**, *357*, 293–299.
25
26
27
28 ¹⁵ Alarma-Estrany, P.; Crooke, A.; Mediero, A.; Peláez, T.; Pintor, J. Sympathetic nervous system
29 modulates the ocular hypotensive action of MT₂-melatonin receptors in normotensive rabbits. *J.*
30 *Pineal Res.* **2008**, *45*, 468–475.
31
32
33
34 ¹⁶ Serle, J.B.; Wang, R. F.; Peterson, W. M.; Plourde, R.; Yerxa, B. R. Effect of 5-MCA-NAT, a
35 putative melatonin MT₃ receptor agonist, on intraocular pressure in glaucomatous monkey eyes. *J.*
36 *Glaucoma* **2004**, *13*, 385–388.
37
38
39
40 ¹⁷ Ismail, S. A.; Mowafi, H. A. Melatonin provides anxiolysis, enhances analgesia, decreases
41 intraocular pressure, and promotes better operating conditions during cataract surgery under topical
42 anesthesia. *Anesth. Analg.* **2009**, *108*, 1146–1151.
43
44
45
46 ¹⁸ Crooke, A.; Huete-Toral, F.; Martínez-Águila, A.; Martín-Gil, A.; Pintor, J. Melatonin and its
47 analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated
48 ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma. *J.*
49 *Pharmacol. Exp. Ther.* **2013**, *346*, 138–145.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5 ¹⁹ Martínez-Águila, A.; Fonseca, B.; Bergua, A.; Pintor, J. Melatonin analogue agomelatine reduces
6 rabbit's intraocular pressure in normotensive and hypertensive conditions. *Eur. J. Pharmacol.* **2013**,
7 *701*, 213–217.
8
9
10
11 ²⁰ Hepler, R. S.; Frank, I. R. Marijuana smoking and intraocular pressure, *JAMA* **1971**, *217*,
12 1392–1392.
13
14
15 ²¹ Panahia, Y.; Manayib, A.; Nikanb, M.; Vazirianc, M. The arguments for and against
16 cannabinoids application in glaucomatous retinopathy. *Biomed. Pharmacother.* **2017**, *86*, 620–627.
17
18
19
20 ²² Porcella, A.; Maxia, C.; Gessa, G. L.; Pani, L. The synthetic cannabinoid WIN55212-2 decreases
21 the intraocular pressure in human glaucoma resistant to conventional therapies. *Eur. J. Neurosci.*
22 **2001**, *13*, 409–412.
23
24
25
26 ²³ Laine, K.; Järvinen, K.; Pate, D. W.; Urtti, A.; Järvinen, T. Effect of the enzyme inhibitor,
27 phenylmethylsulfonyl fluoride, on the IOP profiles of topical anandamides. *Invest. Ophthalmol. Vis.*
28 *Sci.* **2002**, *43*, 393–397.
29
30
31
32
33 ²⁴ Cairns, E. A.; Baldrige, W. H.; KellyM. E. M. The endocannabinoid system as a therapeutic
34 target in glaucoma. *Neural Plast.* **2016**, Article ID 9364091.
35
36
37
38 ²⁵ Piomelli, D. The molecular logic of endocannabinoid signaling. *Nat. Rev. Neurosci.* **2003**, *4*,
39 873–884.
40
41
42 ²⁶ Labar, G.; Michaux, C. Fatty acid amide hydrolase: from characterization to therapeutics. *Chem.*
43 *Biodivers.* **2007**, *4*, 1882–1902.
44
45
46 ²⁷ Miller, S.; Leishman, E.; Oehler, O.; Daily, L.; Murataeva, N.; Wager-Miller, J.; Bradshaw, H.;
47 Straiker, A. Evidence for a GPR18 role in diurnal regulation of intraocular pressure. *Invest.*
48 *Ophthalmol. Vis. Sci.* **2016**, *57*, 6419–6426.
49
50
51
52 ²⁸ Rivara, S.; Lodola, A.; Mor, M.; Bedini, A.; Spadoni, G.; Lucini, V.; Pannacci, M.; Frascini, F.;
53 Scaglione, F.; Ochoa Sanchez, R.; Gobbi, G.; Tarzia, G. N-(Substituted-anilinoethyl)amides:
54
55
56
57
58
59
60

design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. *J. Med. Chem.* **2007**, *50*, 6618–6626.

²⁹ Spadoni, G.; Bedini, A.; Lucarini, S.; Mari, M.; Caignard, D.-H.; Boutin, J. A.; Delagrangé, P.; Lucini, V.; Scaglione, F.; Lodola, A.; Zanardi, F.; Pala, D.; Mor, M.; Rivara, S. Highly potent and selective MT₂ melatonin receptor full agonists from conformational analysis of 1-benzyl-2-acylaminomethyl-tetrahydroquinolines. *J. Med. Chem.* **2015**, *58*, 7512–7525.

³⁰ Rivara, S.; Pala, D.; Lodola, A.; Mor, M.; Lucini, V.; Dugnani, S.; Scaglione, F.; Bedini, A.; Lucarini, S.; Tarzia, G.; Spadoni, G. MT₁-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-[(3-Osubstituted) anilino]alkyl}amides. *ChemMedChem* **2012**, *7*, 1954–1964.

³¹ Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Mor, M.; Rivara, S.; Plazzi, P. V.; Park, C.; Kathuria, S.; Piomelli, D. Design, synthesis, and structure-activity relationship of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. *J. Med. Chem.* **2003**, *46*, 2352–2360.

³² Mor, M.; Rivara, S.; Lodola, A.; Plazzi, P. V.; Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Kathuria, S.; Piomelli, D. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. *J. Med. Chem.* **2004**, *47*, 4998–5008.

³³ Righi, M.; Bedini, A.; Piersanti, G.; Romagnoli, F.; Spadoni, G. Direct, one-pot reductive alkylation of anilines with functionalized acetals mediated by triethylsilane and TFA. straightforward route for unsymmetrically substituted ethylenediamine. *J. Org. Chem.* **2011**, *76*, 704–707.

³⁴ Alcantara-Contreras, S.; Baba, K.; Tosini, G. Removal of melatonin receptor type 1 increases intraocular pressure and retinal ganglion cells death in the mouse. *Neurosci. Lett.* **2011**, *494*, 61–64.

- 1
2
3
4
5 ³⁵ Mileni, M.; Kamtekar, S.; Wood, D. C.; Benson, T. E.; Cravatt, B. F.; Stevens, R. C. Crystal
6 structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a
7 deacylating water molecule and insight into enzyme inactivation. *J. Mol. Biol.* **2010**, *400*, 743–754.
8
9
10
11 ³⁶ Cheng, Y.; Prusoff W. H. Relationship between the inhibition constant (K_i) and the concentration
12 of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction. *Biochem. Pharmacol.*
13 **1973**, *22*, 3099–3108.
14
15
16
17 ³⁷ Pala, D.; Scalvini, L.; Lodola, A.; Mor, M.; Flammini, L.; Barocelli, E.; Lucini, V.; Scaglione, F.;
18 Bartolucci, S.; Bedini, A.; Rivara, S.; Spadoni, G. Synthesis and characterization of new bivalent
19 agents as melatonin- and histamine H_3 -ligands. *Int. J. Mol. Sci.* **2014**, *15*, 16114–16133.
20
21
22
23
24 ³⁸ Rivara, S.; Mor, M.; Silva, C.; Zuliani, V.; Vacondio, F.; Spadoni, G.; Bedini, A.; Tarzia, G.;
25 Lucini, V.; Pannacci, M.; Fraschini, F.; Plazzi, P. V. Three-dimensional quantitative structure-
26 activity relationship studies on selected MT_1 and MT_2 melatonin receptor ligands: requirements for
27 subtype selectivity and intrinsic activity modulation. *J. Med. Chem.* **2003**, *46*, 1429–1439.
28
29
30
31
32
33 ³⁹ Nucci, C.; Bari, M.; Spanò, A.; Corasaniti, M.; Bagetta, G.; Maccarrone, M.; Morrone, L. A.
34 Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure
35 control to neuroprotection. *Prog. Brain Res.* **2008**, *173*, 451–464.
36
37
38
39
40 ⁴⁰ Nucci, C.; Gasperi, V.; Tartaglione, R.; Cerulli, A.; Terrinoni, A.; Bari, M.; De Simone, C.; Agrò,
41 A. F.; Morrone, L. A.; Corasaniti, M. T.; Bagetta, G.; Maccarrone, M. Involvement of the
42 endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats.
43 *Invest. Ophthalmol. Vis. Sci.* **2007**, *48*, 2997–3004.
44
45
46
47
48 ⁴¹ Agorastos, A.; Huber, C. G. The role of melatonin in glaucoma: implications concerning
49 pathophysiological relevance and therapeutic potential. *J. Pineal Res.* **2011**, *50*, 1–7.
50
51
52
53 ⁴² Makriyannis, A.; Nikas Spyridon, P.; Alapafuja Shakiru, O.; Shukla Vidyanand, G. Preparation
54 of Cyclic Compounds as Therapeutic Fatty Acid Amide Hydrolase Inhibitors That Modulate the
55 Cannabinergic System. PCT Int. Appl., WO 2008013963 A2, [Jan 31, 2008](#).
56
57
58
59
60

- 1
2
3
4
5 ⁴³ Masseroni, D.; Mosca, S.; Mower, P. M.; Blackmond, D. G.; Rebek, J. Cavitands as reaction
6 vessels and blocking groups for selective reactions in water. *Angew. Chem. Int. Ed. Engl.* **2016**, *55*,
7 8290–8293.
8
9
10
11 ⁴⁴ De Simone, A.; Russo, D.; Ruda, G. F.; Micoli, A.; Ferraro, M.; Di Martino, R. M. C.; Ottonello,
12 G.; Summa, M.; Armiotti, A.; Bandiera, T.; Cavalli, A.; Bottegoni, G. Design, synthesis, structure–
13 activity relationship studies, and three-dimensional quantitative structure–activity relationship (3D-
14 QSAR) modeling of a series of *O*-biphenyl carbamates as dual modulators of dopamine D₃ receptor
15 and fatty acid amide hydrolase. *J. Med. Chem.* **2017**, *60*, 2287–2304.
16
17
18
19
20
21
22 ⁴⁵ Bracey, M. H.; Hanson, M. A.; Masuda, K. R.; Stevens, R. C.; Cravatt, B. F. Structural
23 adaptations in a membrane enzyme that terminates endocannabinoid signaling. *Science* **2002**, *298*,
24 1793–1796.
25
26
27
28
29 ⁴⁶ Schrödinger Release 2015-4: Schrödinger Suite 2015-4 Protein Preparation Wizard; Epik,
30 Schrödinger, LLC, New York, NY, 2015; Impact, Schrödinger, LLC, New York, NY, 2015; Prime,
31 Schrödinger, LLC, New York, NY, **2015**.
32
33
34
35 ⁴⁷ Shivakumar, D.; Williams, J.; Wu, Y.; Damm, W.; Shelley, J.; Sherman, W. Prediction of
36 absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS
37 force field. *J. Chem. Theory Comput.* **2010**, *6*, 1509–1519.
38
39
40
41
42 ⁴⁸ Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and testing of the OPLS all-
43 atom force field on conformational energetics and properties of organic liquids. *J. Am. Chem. Soc.*
44 **1996**, *45*, 11225–11236.
45
46
47
48 ⁴⁹ Schrödinger Release 2015-4: Maestro, Schrödinger, LLC, New York, NY, **2015**.
49
50
51 ⁵⁰ Schrödinger Release 2015-4: LigPrep, Schrödinger, LLC, New York, NY, **2015**.
52
53
54 ⁵¹ Schrödinger Release 2015-4: Glide, Schrödinger, LLC, New York, NY, **2015**.
55
56
57 ⁵² Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky,
58 M. P.; Knoll, E. H.; Shaw, D. E.; Shelley, M.; Perry, J. K.; Francis, P.; Shenkin, P. S., Glide: a new
59
60

1
2
3
4
5 approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy *J.*
6
7 *Med. Chem.* **2004**, *47*, 1739–1749.

8
9 ⁵³ Schrödinger Release 2015-4: MacroModel, Schrödinger, LLC, New York, NY, **2015**.

10
11 ⁵⁴ Schrödinger Release 2015-4: Prime, Schrödinger, LLC, New York, NY, **2015**.

12
13 ⁵⁵ Nonno, R.; Pannacci, M.; Lucini, V.; Angeloni, D.; Fraschini, F.; Stankov, B. M. Ligand efficacy
14 and potency at recombinant human MT₂ melatonin receptors: evidence for agonist activity of some
15 MT₁-antagonists. *Br. J. Pharmacol.* **1999**, *127*, 1288–1294.

16
17
18 ⁵⁶ Nonno, R.; Lucini, V.; Pannacci, M.; Mazzucchelli, C.; Angeloni, D.; Fraschini, F.; Stankov, B.
19 M. Pharmacological characterization of the human melatonin Mella receptor following stable
20 transfection into NIH3T3 cells. *Br. J. Pharmacol.* **1998**, *124*, 485–492.

21
22
23 ⁵⁷ Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of
24 protein utilizing the principle of protein–dye binding. *Anal. Biochem.* **1976**, *72*, 248–254.

25
26
27 ⁵⁸ Spadoni, G.; Balsamini, C.; Bedini, A.; Diamantini, G.; Di Giacomo, B.; Tontini, A.; Tarzia, G.;
28 Mor, M.; Plazzi, P. V.; Rivara, S.; Nonno, R.; Pannacci, M.; Lucini, V.; Fraschini, F.; Stankov, B.
29 M. 2- [N-Acylamino(C1-C3)alkyl]indoles as MT₁ melatonin receptor partial agonists, antagonists,
30 and putative inverse agonists. *J. Med. Chem.* **1998**, *41*, 3624–3634.

31
32
33 ⁵⁹ Wallez, V.; Durieux-Poissonnier, S.; Chavatte, P.; Boutin, J. A.; Audinot, V.; Nicolas, J. P.;
34 Bennejean, C.; Delagrangé, P.; Renard, P.; Lesieur, D. Synthesis and structure–affinity-activity
35 relationships of novel benzofuran derivatives as MT(2) melatonin receptor selective ligands. *J.*
36
37 *Med. Chem.* **2002**, *45*, 2788–2800.

38
39
40 ⁶⁰ Wilhelmus K. R. The Draize eye test. *Surv. Ophthalmol.* **2001**, *45*, 493–515.

41
42
43
44
45
46
47
48
49
50
51
52 **Table of Contents Graphic**

